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ABSTRACT 
This research features the isolation, structural elucidation, and synthesis of natural products 
from rare and endangered plant species and marine sponges.   
Part I elaborates the identification of bioactive phytochemicals from several rare or 
endangered plant species including Lindera melissifolia, Rhododendron brachycarpum, and 
Diplostephium rhododendroides.  Worldwide at least 13% of known flora are endangered or 
threatened and the United States Department of Agriculture (USDA) reported that there are over 
780 endangered or threatened plant species in the US and its territories. The essential oil and 
solvent extracts from L. melissifolia (pondberry) drupes were gathered, purified, and analyzed by 
various spectrometric techniques. The essential oil exhibited a significant dose dependent repellent 
activity against ticks reported to be vectors of significant pathogenic human diseases such Lyme 
disease.  A Korean endangered plant R. brachycarpum was also rigorously investigated for 
bioactive molecules. R. brachycarpum is a broad-leaved shrub native to northern parts of Korea 
and Japan. The high mobility group box 1 protein (HMGB1) could be a specific target for the 
discovery of effective agents to alleviate severe sepsis. The first bicyclic megastigmane glucoside 
rhododendroside A was isolated from the leaves of R. brachycarpum. Gauge-invariant atomic 
orbital (GIAO) NMR chemical shift calculations were implemented for elucidation of 
stereochemical details of rhododendroside A with accuracy improved by application of DP4 
analysis.  One of the rare South American plant species D. rhododendroides Hieron. afforded 
diplostephiosides A and B. These secondary metabolites exerted inhibitory activity of protein 
tyrosine phosphatase 1B (PTP1B) that has captured widespread attention in development of agents 
iii 
 
for the treatment of metabolic disorders. Comprehensive induced-fit docking simulations were 
implemented with diplostephiosides A and B and they demonstrated excellent docking scores with 
the allosteric binding sites.   
Part II delineates not only the characterization of the stereostructure of BRCA1-IRIS (IRIS) 
inhibitory peptide exhibiting potent in vivo cytotoxic activity on  triple-negative breast cancer 
(TNBC) but also the partial synthesis of a sponge-derived cytotoxic drug prototype for treatment 
of pancreatic cancer. Breast cancer is the second most diagnosed cancer in American women. 
Based on a recent study corroborating that the oncogenicity of IRIS resides with the intron 11 
peptide domain, an IRIS-inhibitory peptide (IRIS-IP), composed of the oncogenic intron sequence 
attached to a nuclear penetrating signal, was designed and its 3D structure was elucidated utilizing 
high-field NMR spectroscopic and computational tools.  Pancreatic cancer has also been 
recognized as a major cause of death in the West.  In 2015, an estimated 48,960 people in the US 
will be diagnosed with pancreatic cancer and about 20,710 will die from the serious disease. 
Discorhabdin X, isolated from Latrunculia species collected in the deep waters off the Aleutian 
Islands, possesses intriguing ring systems and exhibited selective cytotoxic activity on pancreatic 
cancer. A partial structural moiety of this antineoplastic molecule is being synthesized to further 
evaluate in vivo cytotoxic activity for the development of a practical drug prototype targeting the 
treatment of pancreatic cancer and its related fatalities.  
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CHAPTER 1: INVESTIGATION OF TICK REPELLENT ACTIVITY OF VOLATILES 
FROM THE SOUTHEASTERN US ENDANGERED PLANT LINDERA MELISSIFOLIA 
(The contents of this Chapter were reprinted or modified from the original article published in 
Phytochemistry with permission from the publisher via Rightslink® service, Copyright 2012 
Elsevier B.V., Confirmation No. 11305540) 
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INTRODUCTION 
 
A recent report on the decline of global biodiversity suggests that the rate has not decreased 
and several factors have worsened the decline.1  The pressure on biodiversity has been recognized 
for several years, yet progress toward limiting exacerbating factors worldwide appears sluggish.  
Globally at least 13% of known flora are endangered or threatened2 and  the United States 
Department of Agriculture (USDA)3 claimed that there are currently at least 780 endangered or 
threatened species of plants in the United States (US) and its territories.  Although environmental 
factors such as habitat destruction, fragmentation, and climate change4 are the most widespread 
causes of plant species endangerment worldwide,4 biological threats such as competition with non-
native species and invasion of fungi,5 viruses,6 and exotic arthropods7 are also significant factors 
driving those species to extinction. 
The Lauraceae are comprised of about 55 genera and over 2000 species are found in the 
family.8 The members are generally known for their high content of essential oils used in the 
perfume and spice industries.8  Several studies on essential oils found in this family reveal 
associated chemistry and a variety of bioactivities.9-13  Lindera melissifolia (Walt.) Blume 
(Lauraceae), commonly known as pondberry, is a member of the Lauraceae family but has not 
been investigated for its potential bioactive constituents.  It is an aromatic, rhizomatous, dioecious 
shrub that grows in seasonally flooded wetlands and on the edges of sinks and ponds in the 
Southeastern US.14,15 The US Fish and Wildlife Service (USFWS) listed pondberry as an 
endangered species in 198616 because of habitat loss.15 
During the past approximately 30 years, Lyme disease has become a major human health 
problem in the US with many cases reported annually.17,18  In New England, the Mid-Atlantic, and 
the Great Lake areas the causative spirochete Borrelia burgdorferi is transmitted by the bite of the 
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blacklegged tick Ixodes scapularis whereas the Pacific blacklegged tick Ixodes pacificus is the 
vector of the pathogenic spirochete on the West Coast.19,20  The lone star tick Amblyomma 
americanum  is another tick species of medical and veterinary importance21 and this arthropod has 
spread from South Central and Southeastern states northward and somewhat westward into the 
Mid-Atlantic US states.22 
With proper application, insect repellents reduce disease transmission caused by arthropod 
vectors.23 N, N-diethyl-3-methylbenzamide (DEET) is a broad-spectrum synthetic repellent that 
has been effective against several species of mosquitoes, chiggers, ticks, and biting flies.24-28   
However, repeated use of synthetic repellents disrupts natural biological systems and promotes 
resistance.23,29 Additionally, DEET has been reported to exert toxic reactions in humans under 
certain circumstances and age groups,30,31 which motivates exploration and development of natural 
product-based repellents. 
Plants are considered to be a source of safe repellents since they may have less harmful 
side effects from regular use.32 A number of essential oils from plants exhibit insect repellent 
properties.32 Natural repellents are commonly regarded to be effective for short durations but some 
botanically based repellents such as p-menthane-3,8-diol from the lemon-scented gum tree 
Corymbia citriodora have recently shown sustained potency for protection against mosquitoes.33,34  
Consequently, more interest has been focused on plant extracts or essential oils as potential 
alternative repellent agents.35 
As part of a conscious effort to conserve plant resources that still exist in the US but are 
threatened with extinction, L. melissifolia is investigated herein for the chemical constituents and 
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potential biomedical herein.  The crude essential oil of fresh pondberry drupes was collected and 
the oil and a hexanes extract were evaluated for tick-repellent activity. 
 
Figure 1. 1H NMR spectrum of pondberry essential oil and the identified major components 
(CDCl3, 400 MHz) (i) (E)-β-ocimene, (ii) (±)-sabinene, (iii) (±)-α-phellandrene, (iv) (±)-limonene, 
(v) p-cymene, (vi) myrcene 
 
RESULTS AND DISCUSSION 
Crude Essential Oil Analysis/ Preliminary Tick Repellent Assay 
Gas chromatography (GC) and GC-MS analyses were used to investigate the components 
of the essential oil and hexanes extract from L. melissifolia drupes (Table 1).  The major 
components of the essential oil were (±)-sabinene (66.2%), (E)-β-ocimene (12.9%), (±)-α-
phellandrene (4.1%), β-caryophyllene (2.6%), (±)-limonene (2.3%), myrcene (2.1%), and p-
cymene (0.5%), the structures of which were confirmed by 1D NMR analysis.  In the 1H NMR 
spectrum (Figure 1), the characteristic and strong resonances for exo-olefinic (4.65–4.84 ppm) 
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and cyclopropyl functional groups (0.66–0.68 ppm) were observed in component (ii), indicating 
the presence of (±)-sabinene which was proven to be the most abundant component in the essential 
oil by GC and GC-MS analyses (Table 1). The presence of a noticeable resonance for component 
(i) at 6.39 ppm displaying typical cis and trans vicinal couplings (dd, J=17.6, 10.7 Hz) implied the 
presence of a monosubstituted vinyl group.  Comparison of the 13C NMR chemical shift values 
and their relative intensities with literature data36 revealed that component (i) is (E)-β-ocimene.  
An aromatic signal resonated at 7.13 ppm (d, J=2.3 Hz) for component (v) suggested the presence 
of a phenyl group.  Further NMR analysis characterized the component as p-cymene.  Additionally, 
normal phase preparative high-performance liquid chromatography (HPLC) provided a minor 
component, trans-sabinene hydrate.36 
The vertical filter paper bioassay was employed to assess repellent potential of the 
pondberry extract against the blacklegged tick I. scapularis and lone star tick A. americanum. 
The essential oil at 0.827 mg extract/cm2 filter paper repelled 74% of the A. americanum nymphs 
(7.40 ± 0.51 of 10 ticks per replicate) and was significantly more repellent than the acetone  
Figure 2. Responses of A. americanum nymphs to pondberry extract (A), DEET (B), and 
acetone (concentration of zero) in vertical filter paper bioassays. Estimated EC50 (A and B) 
and EC95 (B only) indicated by arrows. 
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control (P = 0.001).  DEET repellence was 93% (9.33 ± 0.67 of 10 ticks per replicate).  The fit 
of the data for determining half maximal effective concentration (EC50) and 95% maximal 
effective concentration (EC95) values, the slopes and intercepts of the regression equations, and 
dispersion parameters for the pondberry essential oil and DEET are shown in Figure 2 and 
Table 2.   
Table 2. Concentrations of L. melissifolia essential oil and DEET estimated to repel 50 and 95% 
of A. americanum nymphs 
a Concentrations as mg extract or DEET/cm2 filter paper; sqrt: square root; SE: standard error 
There was no EC95 determined for repellency of the pondberry essential oil against ticks 
because the necessary proportion of ticks was not repelled.  The slope of the regression equation 
for DEET was significantly higher (P = 0.001) than that of the tested essential oil.  At 0.413 mg/cm2
filter paper, the examined essential oil repelled significantly more I. scapularis adults per replicate 
(P< 0.0001) with an average of 9.75 ± 0.25 (97.5%) ticks repelled compared to the acetone controls 
with 1.67 ± 0.33 (16.1%) adults repelled.  This contrasts with A. americanum which required an 
estimated 0.668 ± 0.05 mg extract/cm2 filter paper to repel half the ticks (Table 2).   
The most abundant component (±)-sabinene was ineffectual (P = 0.3168) against A. 
americanum nymphs at 2000 nmole/cm2 filter paper repelling an average of 1.33 ± 0.88 (13.3%) 
ticks per replicate.  However, the same concentration of trans-sabinene hydrate repelled an average 
of 5.0 ± 1.0 (50%) A. americanum nymphs per replicate (P = 0.0398).  Pondberry extract is clearly 
repellent to A. americanum and I. scapularis and apparently more so to I. scapularis.  Other 
Sample Concentration a (±SE) Intercept (±SE) Slope (±SE) 
Dispersion 
Parameter 
Essential 
Oil 
EC50 0.668 (sqrt)  (±0.050) -3.3820 (±0.695) 5.062 
(±1.051) 2.050 EC95 1.250 (sqrt )  (±1.250) 
DEET EC50 0.339 (sqrt)  (±0.058) -2.546 (±0.719) 7.501 
(±1.640) 2.663 EC95 0.731 (sqrt)  (±1.022) 
7 
repellents (e.g. DEET, SS220) tested in the vertical filter paper bioassay required higher 
concentrations to repel A. americanum nymphs than to repel I. scapularis nymphs.37  A minor 
constituent, trans-sabinene hydrate (0.2% of the pondberry essential oil), showed some moderate 
repellent activity against A. americanum and may act in conjunction with other minor components. 
Figure 3. Stacked GC chromatograms of fractions generated by fractional freezing at -20, -42, -
61, and -200 °C (from top to bottom) 
Enrichment of Active Components in Pondberry Essential Oil 
After the crude pondberry oil was shown to be an effective repellent against ticks, a solvent-
efficient method was devised to enrich the active components.   Fractional freezing, which has 
been traditionally utilized for purifying solvents using their different freezing points,38,39 was 
employed to separate groups of volatile components from the pondberry drupes in this study 
(Figure 3 and Table 3).  The stacked GC-MS chromatograms of fractions generated by the 
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fractional freezing technique are shown in Figure 3 and components in each fraction were 
identified using the aforementioned method (Table 3).  The most abundant monoterpene in the 
crude oil was (±)-sabinene (retention time: 10-11 min, Figure 3) and likewise it dominated all but 
the -20 °C fraction (Table 3).  Fractions collected at -20 °C and -42 °C repelled the A. americanum 
ticks to a similar extent as the crude oil (Figure 4), indicating that fractional freezing was effective 
in accumulating tick repellent components from the essential oil.  Comparative analysis of each 
fraction (Figure 5 and Table 3) identified previously reported tick repellents [geraniol (S), 
citronellol (AF), geranyl acetate (AD), citronellal (Q), terpinen-4-ol (U), and citronellyl acetate 
(AB)]40 and suggested that additional components [myrcene  (F), bornyl acetate (T), β-
caryophyllene (W), α-humulene (X), germacrene D (Y), and β-elemene (AE)] also possess 
repellent activity. 
 
Figure 4. Mean numbers of A. americanum ticks repelled by pondberry crude oil, fractions (-20, 
-42, -61, and -200 °C), and acetone in vertical filter paper bioassay. Columns with the same number 
of asterisks do not differ significantly (P > 0.05) according to analysis of variance. 
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Table 3. Components (%) identified in the essential oil fractions generated by fractional freezing 
technique. *tr=trace 
% Calculated from areas of each peaks corresponding to each components on GC chromatogram; 
tr : trace (< 0.1%); Some components may exist as racemic mixtures  
Components Code
Fractions by Fractional Freezing 
-20 °C -42 °C -61 °C -200  °C 
α-pinene A  3.20 7.27 7.13 
α-thujene B  1.52 5.46 3.47 
camphene C  0.45   
β-pinene D 0.28 0.32 2.67 2.87 
sabinene E 9.23 61.42 62.89 70.93 
myrcene F 0.43 1.30   
α-phellandrene G 0.53 6.66 4.91 2.70 
α-terpinene H 0.47 0.50 4.56 2.16 
limonene I  3.87 1.10 *tr 
1,8-cineole J 8.78 1.39 0.85 2.50 
(E)-β-ocimene K 3.53  1.21 1.76 
γ-terpinene L 1.64 11.04 7.14 4.71 
p-cymene M 3.30 2.47 0.76 1.77 
2-methylbutyl 2-methyl butyrate N  0.48   
alloocimene O  0.42   
terpinolene P 0.52 0.87 1.18  
citronellal Q 0.54 0.50   
linalool R 2.39    
geraniol S 0.55    
bornyl acetate T 1.90 0.22   
terpinen-4-ol U 28.90 0.65   
α-terpinyl acetate V 1.87    
β-caryophyllene W 13.80 1.69   
α-humulene X 0.90 0.08   
germacrene D Y 2.30 0.33   
pregeijerene B Z  0.12   
sabina ketone AA 0.30    
citronellyl acetate AB 3.10 0.29   
α-copanene AC 0.37    
geranyl acetate AD 1.22    
β-elemene AE 0.61 0.05   
citronellol AF 8.34 0.17   
caryophyllene oxide AG 4.21    
10 
 
Figure 5. Scaled distribution of potential tick repellent components in the fractions generated by 
fractional freezing. The components detected in only one fraction were excluded for more relevant 
analysis. The entire list of components is shown in Table 3. 
 
CONCLUSION 
GC and GC–MS analyses of the essential oil from L. melissifolia drupes identified various 
mono- and sesqui-terpenoids (Table 1). The major constituent of the pondberry essential oil and 
its hexanes extract was (±)-sabinene.  The NMR fingerprinting process coupled with GC and GC-
MS verified that (E)-β-ocimene, (±)-sabinene, (±)-α-phellandrene, (±)-limonene, p-cymene, and 
myrcene were characteristic markers of the essential oil from pondberry (Figure 1).  The essential 
oil repelled both the lone star and blacklegged ticks, which indicates it could be developed into a 
nature-derived broad spectrum repellent.  Fractional freezing was verified to be an effective and 
solvent-efficient method to accumulate the tick repellent components in the pondberry essential 
oil.  Although extraction with hexanes may provide a similar product (Table 1) it is not clear from 
A B D E F G H I J K L M P Q T U W X Y AB AE AF
-200  °C 7.1 3.5 2.9 71 2.7 2.2 2.5 1.8 4.7 1.8
-61 °C 7.3 5.5 2.7 63 4.9 4.6 1.1 0.9 1.2 7.1 0.8 1.2
-42 °C 3.2 1.5 0.3 61 1.3 6.7 0.5 3.9 1.4 11 2.5 0.9 0.5 0.2 0.7 1.7 0.1 0.3 0.3 0.1 0.2
-20 °C 0.3 9.2 0.4 0.5 0.5 8.8 3.5 1.6 3.3 0.5 0.5 1.9 29 14 0.9 2.3 3.1 0.6 8.3
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
R
el
at
iv
e 
Pr
es
en
ce
 in
 F
ra
ct
io
ns
 (%
)
11 
 
our tests if the hexanes extract would be active as a tick repellent.  Based on our analysis of the 
fractions generated by fractional freezing, β-caryophyllene (W), α-humulene (X), germacrene D 
(Y), and β-elemene (AE) warrant further investigation as tick repellents (Figure 5).  Although the 
reported compounds may be readily obtained from other plant sources or synthetic routes, 
agricultural techniques involving strain selection based on the metabolome of the plant may also 
satisfy supply requirements.  Additionally, the endangered plant metabolome would provide a 
valuable tool for strain selection for disease and insect resistance.  Thus utilization of products 
obtained from endangered or threatened plant species can potentially support their conservation 
and commercial development. 
EXPERIMENTAL SECTION 
General Experiments 
NMR spectra were obtained using a Bruker Avance 400 MHz spectrometer referenced by 
residual dichloromethane and chloroform resonances. Precoated silica gel 60 F254 plates from 
Merck were used for thin-layer chromatography (TLC). Pentane and dichloromethane (4:1) was 
used to develop TLC.  A vanillin-sulfuric acid stain and iodine were utilized for visualizing TLC. 
The application of HPLC was carried out with a Phenomenex silica column (10 × 250 mm, 5 μm) 
for semi-preparative injections with a Waters dual pump model 510 (flow rate 8 mL/min) and a 
UV absorbance detector model 486. Each fraction was collected employing a Foxy 200 fraction 
collector with one minute increment and identified by TLC.  DEET and trans-sabinene hydrate 
used for the tick assay were purchased from Sigma-Aldrich. The major compound (±)-sabinene 
was isolated from the pondberry essential oil with standard chromatography techniques.  In 
addition to the purchased trans-sabinene hydrate, the monoterpenoid was purified from the 
pondberry crude oil utilizing an HPLC method elaborated above. 
12 
 
Plant Material  
The drupes of L. melissifolia (5 kg) were collected in September 2009 at the Flooding 
Research Facility (FRF)41 on USFWS land in Sharkey Co., MS, jointly maintained by the USFWS 
and US Forest Service. The species was authenticated by Danny Skojac and Tracy Hawkins (US 
Forest Service).  The drupe sample was combined from plants of nine female clones previously 
collected from the Delta National Forest, Sharkey Co., MS and USFWS property in Bolivar Co., 
MS. These clones were reproduced from tissue culture42 and planted into the FRF for a large-scale 
physiology experiment.  A voucher specimen (# 01157) has been deposited at the Herbarium of 
the US Forest Service Southern Hardwoods Laboratory, Washington Co., MS.  
Essential Oil Extraction   
Pondberry drupes (5 kg) were coarsely ground in a blender and placed in the chamber of a 
Speed Vac® (SC210A, Thermo Scientific, Waltham, MA) evaporator.  The essential oil was 
collected in the glass chamber of a refrigerated vapor trap (ca. 100 °C) (RVT 4104, Thermo 
Scientific, Waltham, MA) under high vacuum.  The essential oil contents of the trap were defrosted 
and collected using a separation funnel or extracted with dichloromethane. Removal of the residual 
solvent was completed by carefully blowing with nitrogen gas.  The amount of the collected crude 
oil was approximately 30 g (0.6% wet weight) and the oil was stored at -20 °C.  The remaining 
material was extracted three times by ultrasound in hexanes, which yielded 300 g of the hexanes 
extract.  
GC, GC-MS, and NMR Analysis of Crude Essential Oil 
The GC-MS analysis was carried out with an Agilent 5975 GC-mass selective detector   
system.  A fused silica capillary column (60 m × 0.25 mm, 0.25 m film thickness, Innowax, HP) 
was used with helium as carrier gas (0.8 mL/min).  The GC oven temperature was kept at 60 C 
13 
 
for 10 min and increased to 220 C at a rate of 4 C/min. This temperature was maintained for 10 
min and increased to 240 °C at a rate of 1 °C/min.  The injector temperature was set at 250 C.  
Mass spectra were recorded at 70 eV with a mass range from m/z 35 to 450.  The GC was carried 
out using an Agilent 6890N GC system. The temperature of the flame ionization detector (FID) 
was 300 C.  To obtain the identical elution order with GC-MS, simultaneous auto-injection was 
performed on a duplicate of the same column applying the consistent operational conditions 
described above.  Relative percentage amounts of the separated components were calculated from 
FID chromatograms.  Identification of the essential oil components was carried out by comparison 
of their relative retention times (tR) with those of authentic samples or by comparison of their 
relative retention index (RRI) to a series of n-alkanes.  Component identification was implemented 
by computer matching against commercial databases (Wiley GC/MS Library, Adams Library, 
MassFinder 3 Library),43,44 and the in-house “Başer Library of Essential Oil Constituents” 
established based on genuine compounds of known essential oils and literature data.45,46  Major 
components of pondberry essential oil, i.e. (E)-β-ocimene, (±)-sabinene, (±)-α-phellandrene, (±)-
limonene, p-cymene, myrcene, and β-caryophyllene were also characterized by comparison of 1H 
and 13C NMR chemical shift data with literature data.36,47 
Tick Repellent Assay 
The tick repellent assay was implemented with reference to previous studies.25,37,48 The A. 
americanum nymphs were obtained from a colony at Oklahoma State University, Stillwater, OK 
and held at 23–24 °C, ≈97% relative humidity (RH) and a photoperiod of 16 : 8 h [Light phase (L) 
: Dark phase (D)].    Test solutions of pondberry extracts were prepared in acetone, (±)-sabinene 
and trans-sabinene hydrate were prepared in ethyl acetate.  The repellent activity of the test 
solutions was evaluated based on the tendency of host-seeking ticks to climb described in detail in 
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previous studies.37  Ticks were tested in replicates of 10 ticks per combination of concentration of 
pondberry extracts or DEET.  The extracts and DEET were tested against five replicates of A. 
americanum at 0.827, 0.413, 0.206, 0.103 and 0 (acetone control) mg/cm2 filter paper.  Four 
replicates of 10 adult I. scapularis ticks each were tested against 0.413 mg pondberry crude extract 
/cm2 and two replicates of 10 ticks and one replicate of 11 ticks against the acetone control.  Three 
replicates of 10 A. americanum nymphs each were tested against 2000 and 0 (ethyl acetate control) 
nmole (±)-sabinene and trans-sabinene hydrate/cm2.  Tests for repellency differences between 
components were conducted using the generalized linear models function of the R software.49  This 
permitted modeling of the counts as samples from binomial distributions using the logit link 
function. The estimated dose to repel 50% and 95% percent of ticks and approximate 95% fiducial 
(inverse regression) confidence limits was estimated using the dose.p function in the package 
MASS.50 
Fractional Freezing  
Four different cold temperature baths (-20, -42, -61, and -200 °C) were generated and high 
vacuum (700 mTorr) was applied to fractionate the collected crude essential oil. The four 
temperatures were produced by a recirculating chiller (-20 °C), acetonitrile (-42 °C) and 
chloroform (-61 °C) cooled by adding dry ice and liquid nitrogen (-200 °C).  The temperatures 
were maintained by adding coolants every 10 min.  Extraction of each collected oil fraction was 
completed as described in the Essential Oil Extraction section. GC-MS analysis of the fractions 
generated by the fractional freezing was carried out with an HP 6890 series equipped with a 
split/splitless capillary injector, an HP 6890 Series injector autosampler, and a DB-5ms column 
(30 m × 0.25 mm × 0.25 μm, Agilent). The GC was interfaced to an HP 5973 quadrupole mass 
selective detector through a transfer line set at 240 °C. The injector temperature was 220 °C and 1 
15 
 
μL injections were performed in the split (1 : 10) mode. The column flow was set at a constant 
pressure of 10 psi, providing a nominal initial flow of 1.2 mL/min with helium as carrier gas. The 
oven temperature was raised from 60 to 300 °C at a rate of 3 °C/min for a total run time of 80 min. 
The filament was operated at 70 eV with an emission current of 35 μA. The multiplier voltage was 
automatically set to 2094 V. The ion source and quadrupole temperatures were set with 230 and 
120 °C, respectively. The acquisition range was m/z 35–800 at 1.95 scans per second, starting 2.5 
min after injection.  Components of the four fractions were identified by the identical fashion 
delineated in the GC, GC-MS and NMR Analysis of Crude Essential Oil section. 
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CHAPTER 2: CONFIGURATIONAL ASSIGNMENTS OF CONFORMATIONALLY 
RESTRICTED MEROTERPENOIDS FROM L. MELISSIFOLIA 
(The contents of this Chapter were reprinted or modified from the original article published in 
Biochim. Biophys. Acta, Gen. Subj. with permission from the publisher via Rightslink® service, 
Copyright 2013 Elsevier B.V., Confirmation No. 11305560)
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INTRODUCTION
 
Endangered plant species are an underutilized source for new chemistry. These discoveries 
ironically hold the potential for development into a commercial application that would justify the 
conservation of those plant species in jeopardy.  This is evidenced by a recent phylogenic analysis 
which shows drug producing plant families are concentrated around families which contain 
endangered species.51 However, the challenge associated with such limited resources often 
prohibits the full elucidation of new structures utilizing conventional techniques such as X-ray 
crystallography or spectrometric techniques.  The discovery of new meroterpenoid-based 
hydroquinones from a US endangered plant provides a unique opportunity in this regard.  Owing 
to the conformationally restricted assemblies, investigation of these hydroquinones permits the 
demonstration of how quantum mechanical (QM) calculations combined with NMR and electronic 
circular dichroism (ECD) studies can assign three dimensional structures in cases where 
investigation of such stereochemical detail might not otherwise be feasible due to mass limitations. 
The endangered status of L. melissifolia found in the Southeastern US prompted our study 
of the plant as an example of how endangered US plants can yield novel chemistry that could 
potentially be lost due to extinction.  The drupes of L. melissifolia commonly called pondberry 
exhibits a dose-dependent tick repellency as discussed in Chapter 1.52  The ethyl acetate extract 
of pondberry drupes exerting anti-infective activities was investigated to identify two new 
hydroquinone-based meroterpenoid hydroquinones named melissifolianes A (1) and B (2) (Figure 
6). The structures of the melissifolianes combine a common 2-(hydroquinone) acetic acid ester 
moiety flanked uniquely by two monoterpenoid units in contrast to a single monoterpenoid moiety 
as reported in Magnolia denudata.53 The limited amounts of the melissifolianes neither enabled 
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assignment of their stereostructure by chemical methods nor facilitated investigation of appropriate 
conditions for crystallization.  However, the conformationally restricted state, associated with the 
acetic ester moiety that bridged hydroquinone and terpenoids moieties, provided the opportunity 
to employ computational methods to establish stereochemical details of those meroterpenoids.  
Herein, we report the use of NMR and ECD analysis coupled with QM calculations for the full 
structural assignment of natural products like the melissifolianes possessing conformationally 
restricted moieties.  
 
Figure 6. Structure of melissifolianes A (1) and B (2) 
 
RESULTS AND DISCUSSION 
The 1H NMR data of melissifolane A (1) (Table 4) showed resonances for isopropyl-type 
methyl protons (δH 0.98, 0.93), two m-coupled aromatic protons (δH 6.58, 6.56), and three allylic 
methyls and one methyl group attached to an oxygenated carbon (δH 1.70, 1.33, 1.63, 1.69). 
Deshielded methyl protons were observed at δH 3.83, suggesting a methyl ester functional group 
which was confirmed by a heteronuclear multiple-bond correlation spectroscopy (HMBC) 
correlation between the protons and ester carbonyl at δC 173.4. The 13C NMR resonances deduced 
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from the heteronuclear single-quantum correlation spectroscopy (HSQC) spectrum indicated a 
benzene ring bearing two oxygenated carbons (δC 148.4, 144.2, 131.2, 117.0, 115.8, 113.3).  
Table 4. 1H and 13C NMR data of melissifolianes A and B (1 and 2). The numberings shown in 
this Table are corresponding to those in Figure 6. 
 1  2 
 1H (multi, J in Hz) 13C  1H (multi, J in Hz) 13C  
1  144.2   146.9 
2  117.0   118.8  
3 6.56 (1H, br d, 2.6) 113.3  6.47 (1H, br d, 2.9) 111.3  
4  148.4   148.5  
5 6.58 (1H, br d, 2.4) 115.8  6.57 (1H, br d, 2.7) 115.8  
6  131.2   131.3  
7 3.31, 3.18 (2H, dd, 14.9, 7.5) 28.3  3.27 (2H, d, 7.5) 28.1  
8 5.28 (1H, t, 7.03) 122.2  5.30 (1H, t, 7.5) 121.9  
9  136.1   136.4  
10 1.69 (3H, s) 16.2  1.68 (3H, s) 16.1  
11 2.04 (2H, m) 39.8  2.05 (2H, m) 39.8  
12 2.10 (2H, m) 26.7  2.12 (2H, m) 26.7  
13 5.12 (1H, t, 5.9) 124.4  5.13 (1H, t, 7.6) 124.3  
14  131.3   131.4  
15 1.70 (3H, s) 25.7  1.70 (3H, s) 25.7  
16 1.62 (3H, s) 17.7  1.62 (3H, s) 17.7  
1' 4.15 (1H, d, 6.2) 43.3  3.98 (1H, dd, 11.3, 6.4) 42.8  
2' 2.28 (1H, ddd, 13.9, 6.1, 2.9) 35.4  2.26, 2.19 (2H, m) 30. 5  
3'  72.3  4.27 (1H, dd, 10.70, 3.69) 79.4  
4' 1.33 (3H, s) 24.6   134.0  
5' 5.80 (1H, d, 9.9 ) 131.7  1.77 (3H, s) 12.2  
6' 5.97 (1H, dd, 9.9, 4.6 ) 134.0  5.53 (1H, t, 7.1) 126.4  
7' 1.93 (1H, m) 40.8  2.79 (2H, t, 6.9) 26.7  
8' 1.63, 1.37 (2H, m) 23.2  5.13 (1H, t, 6.8) 122.3  
9' 1.66 (1H, m) 31.7   132.1  
10' 0.93 (3H, d, 6.7) 20.9  1.66 (3H, s) 17.8  
11' 0.98 (3H, d, 6.5) 21.0  1.72 (3H, s) 25.7  
12'  173.4   174.1  
13' 3.83 (3H, s) 51.9  3.77 (3H, s) 52.2  
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The inspection of HMBC and double quantum filter-correlation spectroscopy (DQF-
COSY) spectra revealed that the gross structure of melissifoliane A (1) was based on a 2-
(hydroquinone)acetic acid ester moiety flanked by two monoterpenoid units (Figure 7A). The 
connectivity between the cyclic terpenoid and 2-(hydroquinone) acetic acid ester groups was 
confirmed by the COSY correlation between H-1' (δH 4.15) and H-2' (δH 2.28), and the HMBC 
correlations between H-1' and C-8' (δC 23.2), and H-3 (δH 6.56) and C-1' (δC 43.3) (Figure 7A). 
The acyclic terpene unit was similarly connected to C-6 of the hydroquinone moiety based on the 
COSY correlation of H-7 (δH 3.31, 3.18) and H-8 (δH 5.28), and the HMBC correlations H-8 and 
C-6 (δC 131.2), H-7 and C-5 (δC 115.8), and H-7 and C-1 (δC 144.2) (Figure 7A). The 
configuration of melissifoliane A (1) was established by utilizing an ensemble of distinctive NMR 
chemical shift values, nuclear Overhauser effect (NOE) correlations, and QM calculation.  The (E) 
C-8–C-9 olefin geometry was assigned based on a characteristic pair of carbon resonances for the 
C-10 methyl and the C-11 methylene at δC 16.2 and 39.8, respectively, and NOE correlations 
Figure 7. (A) Key HMBC 
(arrows) and COSY (bold lines) 
and (B) Key NOEs (dotted 
lines) of melissifoliane A (1)
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between H2-7 (δH 3.31, 3.18) and H3-10 (δH 1.69), and H-8 (δH 5.28) and H2-11 (δH 2.04) (Figure 
7B).  
The relative configuration of the hydroxylated monoterpenoid moiety was established 
based on the NOE correlations between H-2' (δH 2.28) and H-9' (δH 1.66), H-4' (δH 1.33) and H-9', 
and H-8' (δH 1.63, 1.37) and H-9'. 3JH-2',H-8'ax (13.9 Hz) and 3JH-2',H-8'eq values (2.9 Hz) suggested 
that the cyclohexene moiety predominantly occupies a half-chair conformation. The orientation of 
the isopropyl group was assigned by the NOE correlations between H-11' (δH 0.98) and the methyl 
ester group H-13' (δH 3.83).  Thus, the relative configuration of the cyclic monoterpenoid unit was 
tentatively assigned 2′S*, 3′S*, 7′S*. 
The observed 3JH1',H2' value (6.2 Hz) indicated a significant conformational change 
associated with the C-1'–C-2' bond, thus indicating that the establishment of C-1' configuration 
would be challenging.  The NMR and QM combined approach was utilized for the comparison 
between experimental and calculated spin-spin coupling constants (SSCCs) to establish the relative 
configuration of C-1'. Geometries were optimized in Jaguar (Schrödinger LLC.) using density 
functional theory (DFT) at the MPW1PW91/6-31G(d,p) level for all six staggered rotamers 
associated with the C-1′–C-2′ bond of diastereomers I and II having different C-1′ configurations 
(Figure 8).  The SSCCs of each rotamer were calculated using the same theory and basis set in 
Gaussian09 (Figure 8, Table 5). To measure experimental homo- and hetero- coupling constants, 
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Figure 8. Diastereomers I and II, 
the plausible structures of 
melissifoliane A (1) with different 
C-1' configurations along with the 
Newman projections for all 
possible staggered rotamers 
associated with the C-1'–C-2' 
bond
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1H NMR, and heteronuclear long-range coupling (HETLOC) were employed. The total absolute 
deviation (TAD)54,55 between the experimental and calculated values (Figure 8, Table 5) verified 
that the calculated SSCCs of diastereomer I in Figure 8 with 1′R*, 2′S*, 3′S*, 7′S* showed a better 
agreement with the experimental J values. 
Table 5. Calculated SSCCs (Hz) of the staggered rotamers of diastereomers I and II shown in 
Figure 8 with the experimental values. 
 Calculated SSCC a 
Exp. b  I II 
 g+ g- anti g+ g- anti 
3JH1', H2' 3.9 5.0 6.9 4.1 4.1 9.3 6.2 
3JH1', C8' 5.9 1.4 4.6 5.3 2.8 1.9 6.5 
2JH1',C2' -4.6 -1.5 -5.2 -1.8 -3.8 -1.9 -5.0 
2JC1',H2' -3.9 -4.0 -4.3 -3.3 -3.8 -4.4 -5.0 
TAD 4.4 10.8 3.5 8.2 8.2 11.4  
a MPW1PW91/6-31G(d,p) calculated J values. b Experimental J values (Exp.) observed from 
HETLOC and 1H NMR spectra. TAD values calculated from (Σ|Jcalc - Jexp|). The lowest TAD 
values in bold are found in diastereomer I. 
The absolute configuration of melissifoliane A (1) was assigned by comparison of the 
calculated and experimental ECD spectra.56-63 The major conformers were generated by selecting 
dihedral angles for the rotamers associated with the C-6–C-7, C-2–C1', C-1'–C-2', and C-1'–C-12' 
bonds. The conformation of the cyclohexene moiety was fixed as a half-chair conformation based 
on the coupling constants analysis described above.  The Amber* force field was used to define 
the initial geometries of generated conformers followed by PM664 semi-empirical optimizations. 
These conformers were subsequently used in DFT B3LYP/6-31G(d,p) calculations to obtain more 
accurate geometries in the gas phase and in MeCN.65,66 The 24 lowest-energy conformers within 
an energy window of 50 kJ/mol (conformers 1–24, for their coordinates see Supplementary Data 
2 in the original article67) exhibited different intramolecular hydrogen bond interactions, involving 
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the C-1 and C-3' hydroxy groups and the C-12' ester oxygen atoms. Such hydrogen bonding 
partially restricted rotation of the C-12'–C-1', C-1'–C-2, and C-1'–C-2' bonds. 
The full array of conformers was used for calculations of the excited state in the gas phase 
and in MeCN using time-dependent density functional theory (TDDFT). The excitation energies 
and rotational strengths of each conformer were Boltzmann-weighted according to the calculated 
Gibbs free energies and subsequently fitted to Gaussian 09 (Gaussian Inc.) functions to simulate 
ECD curves. The major conformers found at the B3LYP/6-31G(d,p) level were further optimized, 
and employed for ECD calculations at the B3LYP/6-311G++(2d,p) level to validate the initial 
ECD calculations at the B3LYP/6-31G(d,p) level.  The experimental ECD spectrum of 
melissifoliane A (1) shows Cotton effects characteristic of the n → π* electronic transition of the 
ester functionality at ca. 300 nm, the 1Lb transition of the aromatic chromophore at ca. 260 nm, 
and the 1La transition of the aromatic chromophore in the 220–240 nm region (Figure 9). Figure 
9 depicts overlays of the experimental ECD spectrum of melissifoliane A (1), the average 
calculated spectrum of the major conformers of melissifoliane A (1) at the B3LYP/6-31G(d,p) and 
B3LYP/6-311++G(2d,p) levels, respectively. The calculated ECD data employing the different 
Figure 9. Overlaid 
experimental and 
averaged calculated ECD 
spectra of melissifoliane 
A (1) utilizing the two 
difference basis sets 
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basis sets shown in Figure 9, taken in conjunction with the experimental ECD curve, was sufficient 
to assign the absolute configuration as 1'R, 2'S, 3'S, 7'S. 
The 1D NMR data of melissifoliane B (2) (Table 4) resembled those of melissifoliane A 
(1), which suggested that it shared structural similarities with the exception of the nature of the 
methyl groups of the C-1' substituent. The acyclic terpene and hydroxylated terpenoid moieties 
were connected to C-6 (δC 131.3) and C-1' (δC 42.8), respectively, using similar DQF-COSY and 
HMBC correlations as described for melissifoliane A (1). The C-8–C-9 olefin geometry was 
established as E based on the NOE correlations between H2-7 (δH 3.27) and H3-10 (δH 1.68), and 
H-8 (δH 5.30) and H2-11 (δH 2.05).  The E geometry of the C-4'–C-6' olefinic bond was assigned 
by the chemical shift values of C3' (δC 79.4) and C5' (δC 12.2) and NOE correlations between H3-
5' (δH 1.77) and H2-7' (δH 2.79), and H-3' (δH 4.27) and H-6' (δH 5.53). Melissifoliane B was 
optically inactive which suggested a racemic mixture, which was confirmed by chiral 
chromatography (Figure 19).  The attempt to assign the relative configuration of melissifoliane B 
(2) using J-based analysis failed because of the lack of a relevant model for phenyl substituents 
and infeasibility in measuring the 3JCH involving quaternary carbons of the hydroquinone moiety. 
Consequently, the relative configuration of melissifoliane B (2) was also established employing 
the identical manner as for 1.68  The gauche+ conformer associated with C-1′–C-2′ exhibited the 
lowest TAD value and this conformer was assembled with the major conformer of the C-2′–C-3′ 
bond identified by J-based analysis (Figure 10). This collectively elucidated the relative 
configuration of melissifoliane B (2) as 1′R* and 3′R*.   
 
CONCLUSIONS 
 Our study of the Lindera melissifolia metabolome exemplifies how new chemistry remains 
undiscovered among the numerous endangered plant species. This also demonstrates how analysis 
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by ECD and NMR techniques combined with various QM calculations is a valuable approach to 
support the stereochemical assignment of molecules possessing conformationally restricted bonds 
linking the different structural moieties.  Utilization of the secondary metabolites obtained from 
other endangered plant species may serve as added justification for conservation of such plants 
given potential socioeconomic value they may generate.  
 
 
 Gauche+ (C-1'–C-2')  Gauche- (C-3'–C-2') 
 Calcd. SSCC a Exp. b   Exp. b 
3JH1', H(H) 11.3 11  3JH(H), H3' 10.7 
3JH1', H(L) 3.2 5.2  3JH(L), H3' 3.7 
3JH1', C3' 2.9 1.5  3JH3', C1' 3 
2JC1', H(H) -3 -4  2JH(H), C3' -6 
2JC1', H(L) -3.1 -4  2JH(L), C3' -4 
TAD 5.6     
Figure 10. The major conformers suggested by QM calculation (C-1′–C-2′, left) and J-based analysis (C-
2′–C-3′, right). H(H) and H(L) indicate 2.26 and 2.19 ppm, respectively. a SSCCs were calculated at  
MPW1PW91/6-31G(d,p). b Experimental J values observed from HETLOC, exclusive COSY (E. COSY), 
and 1H NMR spectra. TAD: See Table 5.  
 
EXPERIMENTAL SECTION  
General Procedures 
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NMR spectra were obtained using a Bruker Avance 400 MHz spectrometer referenced by 
residual dichloromethane and chloroform resonances. Homo- and hetero-nuclear coupling 
constants were measured using 1H NMR, E. COSY, and HETLOC. Optical rotations were 
measured on a Rudolph Autopol V polarimeter. UV-vis spectra were recorded on an Agilent 1100 
series diode array and multiple wavelength detectors. The LC-MS analyses were performed using 
an Agilent 1100 HPLC system equipped with a Phenomenex Luna 5 m C8(2) column (4.6 × 150 
mm), an MeOH/H2O (0.1% HCOOH) gradient solvent system, and a Bruker Daltonics microTOF 
mass spectrometer. For chiral chromatography, an Astec Chirobiotic R column (4.6 × 100mm) 
was utilized eluting with a 55% MeOH/H2O isocratic solvent condition (20 mM NH4Ac, 35 °C). 
HRESIMS spectra were obtained employing a Bruker Daltonics microTOF mass spectrometer 
with electrospray ionization.  Column chromatography was conducted using silica gel 60 (40–63 
m particle size) and reverse phase (RP)-18 (40–63 m particle size). Precoated TLC silica gel 60 
F254 plates (Merck) were used for TLC. HPLC was performed on a Waters System equipped with 
Waters 2487 dual absorbance detector. Experimental ECD spectrum was acquired at 5 °C with an 
Olis CD spectrophotometer. The concentration of the sample was 500 μg/mL in MeCN and the 
path length was 5 mm. 
 
Extraction and Purification  
For the collection and authentication of the plant material, see Plant Material section in 
Chapter 1. The dried ripe drupes of L. melissifolia were coarsely ground and extracted with EtOAc, 
and the extract was dried under reduced pressure to give 100 g of crude extract. The extract was 
fractionated on silica gel eluted with hexanes-EtOAc (100:0, 80:20, 50:50 and 0:100) and then 
with EtOAc-MeOH (80:20, 50:50 and 0:100) to afford 10 fractions, respectively. Fractions 6–9 
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exhibited significant anti-infective activities and these active fractions were further 
chromatographed by normal phase HPLC [Phenomenex Luna silica, 50 × 250 mm, 10 μm, flow 
rate 30 mL/min] with a gradient elution of hexanes-EtOAc (1:0 to 8:2 over 120 min) and, finally, 
by RP HPLC [Waters C18 20 × 250 mm, 10 μm, flow rate 10 mL/min; Phenomenex C18 5 × 250 
mm,  5 μm, flow rate 1 mL/min] using a gradient elution of H2O-MeOH (1:1 to 0:1 over 110 min) 
to obtain the pure compounds. 
 Melissifoliane A (1) 
Melissifoliane A (1, tR = 46 min), a pale yellowish oil, had the molecular formula C29H42O5 
deduced from HRESIMS data (obsd [M+Na]+-H2O at m/z 475.2842, calcd [M+Na]+-H2O at m/z 
475.2819; obsd [2M+Na]+-H2O at m/z 927.5725, calcd [2M+Na]+-H2O = 927.5751).  The specific 
rotation ([]23D) was established as +54.0 (c 0.2, MeCN). For 1H and 13C NMR data, see Table 4. 
 Melissifoliane B (2) 
Melissifoliane B (2, tR = 45 min), a pale yellowish oil, had the molecular formula C29H42O5 
as deduced from HRESIMS results (obsd [M+Na]+-H2O at m/z 475.2852, calcd [M+Na]+-H2O at 
m/z 475. 2819; obsd [2M+Na]+-H2O at m/z 925.5530, calcd [2M+Na]+-H2O =927.5751). For 1H 
and 13C NMR data, see Table 4. 
 
QM Computational Calculation 
ECD calculation 
Initial conformational analysis was conducted using the Amber* force field in the 
MacroModel program included in the Schrödinger software package (Schrödinger LLC.). The 
resulting structures were optimized using the PM6 semi-empirical method in the Gaussian 09 
package (Gaussian Inc.). The PM6-optimized structures were further optimized using DFT gas-
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phase calculations.  The geometry optimizations and frequency calculations of the conformers 1–
24 were implemented using the hybrid DFT method B3LYP with the 6-31G(d,p) basis set, 
specifying tight convergence. The major conformers (conformers 1, 3, 5, 6, 13, 14, 15, 16, 17 and 
19) from the optimization process were further minimized at the B3LYP/6-311++G(2d,p) level  
with tight convergence in order to validate the effects of including a larger basis set. Separate 
optimizations were carried out starting from the PM6-optimized structures using the conductor-
like polarizable continuum solvation model with a dielectric constant representing MeCN. The 
excited state calculations were performed using the TDDFT method with B3LYP with each of the 
two basis sets [i.e., 6-31G(d,p) and 6-311++G(2d,p)]. The generated excitation energies and 
rotational strengths were weighted using Boltzmann averaging based on the calculated Gibbs free 
energy of each conformer and then fitted with a Gaussian function to generate the computed ECD 
spectra. These raw computed data were visualized utilizing SpecDis69 for comparison to the 
experimental ECD spectrum. 
  
SSCC calculation 
Geometries were optimized in Jaguar (Schrödinger LLC.) using DFT at the 
MPW1PW91/6-31G(d,p) level for all six staggered rotamers of each diastereomer associated with 
C-1'–C-2' of melissifolianes A and B (1 and 2). The SSCC of each rotamer was calculated using 
the same theory and basis set in Gaussian09.70  The total absolute deviation (TAD)54,55  between 
experimental and calculated values was used to suggest the most relevant conformers. 
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Figure 11. 1H NMR (top) and DQF-COSY (bottom) spectra of melissifoliane A (1) 
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Figure 12. HSQC (top) and HMBC (bottom) spectra of melissifoliane A (1) 
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Figure 13. NOESY (top) and HETLOC (bottom) spectra of melissifoliane A (1) 
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Figure 14. HRESIMS spectrum of melissifoliane A (1) 
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Figure 15 . 1H NMR (top) and DQF-COSY (bottom) spectra of melissifoliane B (2) 
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Figure 16. HSQC (top) and HMBC (bottom) spectra of melissifoliane B (2) 
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Figure 17. NOESY (top) and E.COSY (bottom) spectra of melissifoliane B (2) 
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Figure 18. TOCSY (top) and HETLOC (bottom) spectra of melissifoliane B (2) 
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Figure 19. The RP chromatogram (Phenomenex C8 5 × 150 mm, 5 μm, flow rate 0.6 mL/min 
using an isocratic elution of 70% MeOH in H2O) (top) and chiral chromatogram (Astec Chirobiotic 
R 4.6 × 100mm, 5 μm, flow rate 0.6 mL/min with an isocratic elution of 55% MeOH in 20 mM 
NH4Ac, pH 6, 35 °C) (bottom) of melissifoliane B (2) 
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Figure 20. HRESIMS spectrum of melissifoliane B (2) 
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CHAPTER 3: DISCOVERY OF DRUG LEADS FOR TREATMENT OF SEPSIS FROM 
THE KOREAN ENDANGERED SPECIES RHODODENDRON BRACHYCARPUM 
(The contents of this chapter were reproduced or edited from the original article published in 
Biochim. Biophys. Acta, Gen. Subj. with permission from the publisher via Rightslink® service, 
Copyright 2014 Elsevier B.V., Confirmation No. 11305580) 
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INTRODUCTION 
 
Endangered plant species are an important resource for exploring novel drug prototypes71 
as discussed in the previous chapters. Rhododendron brachycarpum G. Don (Ericaceae) is a broad-
leaved shrub native to northern Korean and central Japan.72  The numbers of this species have been 
drastically diminished due to climate change, leading to its classification as an endangered and 
rare species in Korea.72 Although R. brachycarpum is traditionally employed in the treatment of 
diseases including cardiovascular, diabetes, hypertension, hepatitis, rheumatoid arthritis, and 
headache,73 only a limited number of studies have been carried out to validate these 
ethnopharmacological uses.74,75 
Sepsis is a systemic and overwhelming inflammatory response of an organism to a local 
infection, potentially progressing to severe sepsis and septic shock with multiple organ failure and 
hypotension.76 The mortality associated with the disease is as high as 50–70%, leading to its 
designation as the number one cause of death in intensive care units worldwide.76  Comprehensive 
anti-inflammatory treatments have not alleviated the disease phenotypes during the last few  
decades.76 The only FDA-approved antiseptic drug drotrecogin alfa (Xigris®) was withdrawn from 
the market due to its questionable efficacy,77 thus stressing the necessity for the search of potential 
antiseptic prototypes with a novel mode of action (MOA). Among the therapeutic strategies 
targeting the mitigation of sepsis,76 enhancement of the integrity of endothelial cells (ECs) has 
emerged as a sensible MOA for treatment of the serious disease.78,79 Disruption of the integrity of 
ECs facilitates leucocytes to access inflamed tissue and hence initiating such vascular 
inflammatory manifestations.78,79 In this regard, high mobility group box 1 (HMGB1) protein 
could be targeted specifically for the exploration of novel antiseptic agents capable of achieving 
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vascular barrier augmentation because of the significant role of the protein in disturbing the barrier 
integrity of ECs, and ultimately inducing severe sepsis and related fatalities.78-80 
In continuing efforts aimed at discovering viable and new drug prototypes from endangered 
species,71-73,81 the isolation and structural characterization of rhododendroside A (1), the first 
bicyclic megastigmane glycoside, is elaborated herein. It is also discussed whether this scaffold 
can be developed into a septic drug lead capable of mitigating HMGB1-induced vascular 
disruption. 
 
RESULTS AND DISCUSSION 
An extract of the leaves of R. brachycarpum was fractionated and purified employing 
various chromatographic techniques, leading to the purification of megastigmane glucosides (1–
5) (Figure 21. (A) Structures of 1–5 from R. brachycarpum and (B) key COSY (▬) and HMBC 
(→) correlations in 1). Compound 1 was obtained as a yellow amorphous powder and the 
molecular formula was established as C19H32O8 based on HRESIMS and 13C NMR data (obsd 
[M+Na]+ at m/z 411.1996, calcd [M+Na]+ at m/z 411.1995). The 1H NMR spectrum (Table 6) 
displayed resonances for an olefinic proton (δH 4.51), an anomeric proton (δH 4.43), an oxymethine 
proton (δH 4.16), an allylic (δH 1.66) and two tertiary and one oxygenated secondary methyl groups 
(δH 1.30, 1.07, 1.03). The 13C NMR spectrum (Table 6) exhibited 19 resonances including six 
carbon resonances belonging to a glucopyranosyl moiety (δC 102.8, 75.1, 78.0, 71.6, 77.8, 62.7), 
two olefinic carbons (δC 149.4, 97.6), an oxymethine carbon (δC 73.2), one quaternary and two 
oxygenated tertiary carbons (δC 81.5, 72.0, 40.7), three methylene carbons (δC 44.7, 41.4, 29.9), 
one allylic (δC 20.0), and two tertiary and one oxygenated secondary methyl carbons (δC 27.4, 
24.6, 22.7). These spectroscopic data are similar to those of icariside B2 (3),82 indicating the 
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presence of a megastigmane glucoside framework in 1. Differences in the NMR data of 3 and 1 
include the disappearance of the proton signals of the conjugated trans-olefinic group and a change 
of the nature of the acetyl methyl group in 3 compared to 1. These differences are compatible with 
a structure of 1 generated from 3 via cyclization of the C-6 methyl vinyl ketocarbonyl functionality 
onto the oxirane moiety. This was confirmed by HMBC correlations between H-8 (δH 4.51) and 
C-6 (δC 72.0), C-7 (δC 29.9), C-9 (δC 149.4), and C-10 (δC 20.0), and between H-7 (δH 2.34, 1.99) 
and C-6 (δC 72.0), C-8 (δC 97.6), and C-9 (δC 149.4) (Figure 21). Such formation of a hexahydro-
4H-chromene moiety leads to a unique cyclomegastigmane scaffold, which has not previously 
been observed in bisnorsesquiterpenoids. The connectivity of the aglycone and monosaccharide 
moieties was confirmed by an HMBC correlation between H-1' (δH 4.43) and C-3 (δC 73.2) (Figure 
21). The coupling constant (J = 7.8 Hz) of the anomeric proton confirmed a β-glucosidic linkage. 
Acid hydrolysis followed by GC analysis confirmed the presence of D-(+)-glucose.  
Figure 21. (A) Structures of 1–5 from R. brachycarpum and (B) key COSY (▬) and HMBC (→) 
correlations in 1 
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Table 6. 1H and 13C NMR data (Exp.) of compound 1 in methanol-d4 and calculated chemical 
shift values (Cal.) of diastereomers I and III  
1H NMR chemical shift values (δH) 13C NMR chemical shift values (δC) 
position a Exp. δH, multi, (J in Hz) 
Cal. Exp. Cal. I b IIIc I b III c 
1    40.7 44.8 44.5 
2ax. 1.76, t, (12.6) 1.90 1.75 44.7 47.7 45.7 
2eq. 1.60, ddd, (12.6, 4.1, 2.4) 1.59 1.50    
3 4.16, tt, (12.6, 4.1) 4.35 4.33 73.2 68.6 69.0 
4ax. 1.82, dd, (13 b.2, 12.6) 1.84 2.03 41.4 44.4 46.6 
4eq. 2.12, ddd, (13.2, 4.1, 2.4) 2.07 2.19    
5    81.5 82.4 82.6 
6    72.0 75.7 75.7 
7α 1.99, m 1.99 1.94 29.9 33.5 33.9 
7β 2.34, m 2.25 2.31    
8 4.51, m 4.61 4.60 97.6 96.5 96.5 
9    149.4 146.6 146.8 
10 1.66, m 
1.68 1.58 
20.0 21.0 21.0 1.77 1.73 
1.54 1.66 
11 1.03, s 
0.94 1.06 
27.4 28.0 28.2 0.97 1.27 
0.96 0.66 
12 1.07, s 
1.19 0.61 
24.6 25.2 25.3 1.46 1.59 
0.68 1.17 
13 1.30, s 
0.89 1.60 
22.7 25.2 24.8 1.63 0.98 
1.49 1.32 
1′ 4.43, d, (7.8) 4.54 4.50 102.8 103.9 104.1 
2′ 3.18, dd, (9.1, 7.8) 3.51 3.51 75.1 76.5 76.6 
3′ 3.39, m 3.74 3.73 78.0 78.1 78.2 
4′ 3.35, m 3.60 3.56 71.6 72.3 72.2 
5′ 3.35, m 3.51 3.51 77.8 77.8 78.2 
6′a 3.90, dd, (11.9, 2.1) 4.08 4.09 62.7 64.9 65.0 
6'b 3.73, dd, (11.9, 5.1) 3.83 3.83    
DP4 (%)  96.3 3.7  70.9 29.1 
a See Figure 21. b,c Calculated chemical shift values for diastereomers I and III shown in Figure 22 
The relative configuration of the aglycone was established via coupling constants and NOE 
correlations. The coupling constants of H-3 (tt, 12.6, 4.1 Hz) suggest that the cyclohexane ring 
occupies either a chair or boat conformation. The relative configuration of C-5 was assigned based 
on the presence of a strong NOE correlation between H-3 (δH 4.16) and H-12 (δH 1.07) and the 
absence of an NOE correlation between H-3 (δH 4.16) and H-13 (δH 1.30) (Figure 22). Based on 
these findings, two plausible diastereomers (diastereomer I: 3S, 5R, 6R; diastereomer II: 3S, 5R, 
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6S) were proposed and minimized with the aforementioned conformational dihedral constraints 
and spatial distance information employing the MMFF94 force field (Schrödinger LLC.) (Figure 
22A). The presence of an NOE correlation between H-12 (δH 1.07) and H-8 (δH 4.51) in 
diastereomer I and the absence of an NOE correlation between H-11 (δH 1.03) and H-13 (δH 1.30), 
but feasible in diastereomer II, support the relative configuration of diastereomer I and confirm its 
structural equivalence with compound 1 (Figure 22A). Owing to the mass limitations of 1, 
definition of the absolute configuration was attempted utilizing GIAO NMR chemical shift 
calculations with accuracy improved by application of DP4 analysis that has been successfully 
applied for investigation of stereochemical details.83-85 Having established the D-glucopyranosyl 
moiety in 1, diastereomers I and III with enantiomeric aglycone moieties were considered (Figure 
22). The major conformers of diastereomers I and III, generated by conformational searches 
employing Macromodel (Schrodinger LLC.), were subjected to gauge-invariant atomic orbital 
(GIAO) shielding constant calculations at the B3LYP/6-31G(d,p) level employing the Gaussian 
09 package (Gaussian Inc.). 
Figure 22. (A) Minimized stereostructures of plausible diastereomers of 1 (yellow dotted lines 
indicate NOE correlations) and (B) their 2D representations  
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The calculated chemical shift values were Boltzmann-averaged based on their relative 
MMFF94 potential energy and these averaged values were used for the calculation of DP4 
probability. According to DP4 analysis (Table 6), Diastereomer I was supported with 98.4% 
probability when chemical shift values of the two nuclei  were taken into consideration, permitting 
assignment of absolute configuration of compound 1 identical to that showed for Diastereomer I. 
Moreover, consistency regarding the 3S-configuration among analogues 2–582,86,87 further supports 
the DP4 prediction of the 3S configuration of 1 when considered in conjunction with a similar 
biosynthetic pathway towards these bisnorsesquiterpenes. As shown in Figure 23, enzymatic 
epoxidation of 5 would stereochemically be directed by the 3β-equatorial substituent, leading to 
formation of oxirane 6 that would be susceptible to successive cyclization and dehydration via 7 
to form 1. On the basis of these findings, the structure of 1 was defined as (3S,5R,6R)-1,1,5,9-
tetramethyl-3-β-D-glucopyranosyloxy-2,3,4,5-tetrahydro-7H-chromen-6-ol, named 
rhododendroside A (1). The known megastigmane glucosides, picrionoside A (2),86 icariside B2 
(3),82 citroside A (4),87 and icariside B6 (5)82 were identified by 1D and 2D NMR analysis and 
confirmed by comparing the physical and spectroscopic data with those in the literature. 
 Figure 23. Plausible biosynthetic pathway for generation of rhododendroside A (1) 
46 
 
Compounds 1–5 were evaluated for their potential to hamper HMGB1-mediated vascular 
disruption as a cause of severe sepsis and associated manifestations.78,79,88 To evaluate actin 
cytoskeletal arrangement activity of 1–5, human umbilical vein endothelial cells (HUVECs) were 
treated with 10 μM of each compound employing immunofluorescence staining of HUVEC 
monolayers with the F-actin labeled fluorescein phalloidin (Figure 24A). The control displayed 
random F-actin distribution throughout cells with actin filament bundles localized at cell 
boundaries (Figure 24A) while vascular barrier disruption triggered by HMGB1 (1 μg/mL) was 
evidenced by the generation of paracellular gaps upon HMGB1 treatment (arrowed in Figure 
24A). Pretreatment with 1, 2, and 5 eliminated HMGB1-induced paracellular gaps and facilitated 
the formation of dense F-actin rings (Figure 24A), protecting vascular barrier integrity from 
HMGB1-induced vascular stress. However, pretreatment with 3 and 4 did not recover the 
HMGB1-mediated paracellular gaps (Figure 24A). To further examine if compounds 1–5 enhance 
barrier integrity of HUVECs, a permeability assay was performed with various concentrations (1–
10 μM). Pretreatment with 1, 2, and 5 (10 μM) restored the levels of permeability to those of the 
negative control (Figure 24B) in HMGB1-stimulated barrier integrity disruption while their 
pretreatment (10 μM) without the vascular stressor did not influence the barrier integrity, 
validating their strong supportive action of vascular barrier integrity (Figure 24B). To verify if the 
observed barrier protective action was associated with HMGB1 signaling through its receptors, 
expression of the associated receptors including toll-like receptors 2 and 4 (TLR2, TLR4) and 
receptor for advanced glycan endproducts (RAGE) was monitored upon pretreatment with 
compounds 1–5 (1–10 μM). Pretreatment of HUVECs with 1, 2 and 5, diminished the HMGB1 
receptors in a dose-dependent manner, implying that the active compounds exerted the vascular 
barrier restorative action via the inhibition of HMGB1 interacting with the receptors (Figure 24C).  
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Phosphorylation of p38 mitogen-activated protein kinase (MAPK) was also evaluated employing 
enzyme-linked immunosorbent assay (ELISA) based on studies validating HMGB1 induces pro-
inflammatory response by promoting phosphorylation of p38.78,79 The treatment of HUVECs with 
HMGB1 significantly enhanced phosphorylation of p38 and this up-regulation was attenuated 
upon the pretreatment with 1, 2, and 5, indicating that they averted HMGB1-induced pro-
inflammatory reactions and consequently maintaining vascular barrier integrity (Figure 24D). 
Overall, these in vitro findings cohesively corroborated the active compounds exerted vascular 
protective potential via inhibition of HMGB1-induced pro- inflammatory response.   
In vivo experiments employing murine models were conducted to confirm the observed in 
vitro vascular barrier protective effects of the examined compounds. Intravenous pretreatment of 
mice with 1–5 (7.7 μg/mouse) was carried out followed by HMGB1 [2 μg/mouse, intravenous 
(i.v.)]-induced barrier disruption in vivo. Compounds 1, 2, and 5, protecting vascular barrier 
integrity in vitro, also restored vascular permeability in vivo upon HMGB1-induced pro-
inflammatory stimuli based on the decreased dye leakage levels to near those of the negative 
control, while compounds 3 and 4 did not suppress the levels of dye leakage (Figure 24A). To 
corroborate in vitro anti-permeability effects of the active compounds, in vivo leukocyte migration 
was evaluated by counting the number of migrated leukocytes into peritoneal cavities upon 
HMGB1-challeged mice models. As shown in Figure 25B, i.v. pretreatment with 1, 2, and 5 
inhibited migration of leukocytes based on the decreased peritoneal leukocytes counts, verifying 
their inhibitory action on leukocytes chemotaxis upon HMGB1-induced inflammatory 
environment. 
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Figure 24. In vitro evaluation of vascular protective action of compounds 1, 2, and 5 against HMGB1 
(1 μg/mL for 16 h)-induced vascular barrier disruption. Data were analyzed upon pretreatment of 
HUVECs with the indicated concentrations for 6 h. (A) Staining for F-actin upon pretreatment of 1–5. 
(B) HMGB1-induced permeability was monitored by assessing the flux of Evans blue bound albumin 
across HUVECs. (C) Influence of 1, 2, and 5 on expression of HMGB1 receptors, and (D) 
phosphorylation of p38 was evaluated by ELISA. (C) White, gray, and black bars indicate expression 
of TLR2, TLR4, and RAGE. Results are indicated with the means ± standard deviations (SDs) of 
different of at least three experiments and *p < 0.05 and **p < 0.01 compared to cells only treated with 
HMGB1 (B–D). 
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             To validate if the active megastigmane glucosides may be developed into practical 
prodrugs for treatment of septic fatalities, they were administered to mice (7.7 μg/mouse) upon 
cecal ligation and puncture (CLP) operation employed to simulate the late stage of severe sepsis.89 
According to the Kaplan–Meier survival analysis,78,79 compounds 1, 2, and 5, demonstrating potent 
vascular barrier protective activity in vitro and in vivo, improved the survival rate to 60, 40, and 
40%, respectively, 132 h after the CLP operation (Figure 25C). In view of these biological findings, 
it is plausible that the megastigmane glucosides restore in vitro and in vivo vascular integrity with 
mitigating HMGB1-induced pro-inflammatory vascular stimuli, ultimately leading to alleviating 
septic lethality. Thus, megastigmane 
glucosides (1, 2 and 5) could be a sensible 
starting point not only for conducting 
further structure-activity relationship 
studies but also developing an effective 
septic agent capable of inhibiting HMGB1. 
Figure 25. (A, B) In vivo vascular 
supportive and antiseptic action of 1–5 (7.7 
μg/mL) upon HMGB1 (2 μg/mouse, i.v.)-
mediated pro-inflammatory environment 
and (C) CLP operation. Effects of 1–5 on 
vascular permeability were measured by the 
amount of Evans blue in peritoneal 
washings (n=5). (A) H and D stand for mice 
groups administered with HMGB1 and 
DMSO, respectively. (B) Anti-migration 
potential (n=5) of 1–5 was evaluated by 
counting the number of migrated leukocytes 
into peritoneal cavities. (C) Anti-lethality 
activity (n=10) of those compounds was 
assessed using a CLP-induced septic shock 
mice model. Control CLP mice (●) and 
sham-operated mice (○) were administered 
sterile saline and survival was monitored 
every six-hour. Results are shown with the 
means ± SDs of three different experiments 
and *p < 0.05 and **p < 0.01 compared to 
mice only treated with HMGB1 (A,B). 
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CONCLUSION 
This Chapter delineates that R. brachycarpum may be the source of a unique scaffold that 
can be developed into an antiseptic lead mitigating HMGB1-induced vascular pro-inflammatory 
stimuli. These results also reaffirm that rare and endangered plant species offer unique 
opportunities to explore novel drug leads, warranting conservation efforts especially in cases 
where modern-day disease challenges are intensifying. 
 
EXPERIMENTAL SECTION 
General Experiments 
NMR experiments were conducted using a Bruker DMX 250 and Bruker DMX 600 
spectrometers (Karlsruhe, Germany) referenced by residual pyridine and methanol signals. 
Specific rotations were recorded using a JASCO DIP-1000 (Tokyo, Japan) and mass spectrometric 
data were obtained utilizing a SYNAPT G2 Waters mass spectrometer (Manchester, U.K.). 
Medium-pressure liquid chromatography (MPLC) was carried out employing Biotage IsoleraTM 
RP C18 SNAP Cartridge KP-C18-HS and normal-phase SNAP Cartridge KP-Sil (340 g, Biotage 
AB, Uppsala, Sweden). The GC analysis was carried out on a Shimadzu-2010 with an SPB-1 
column (0.25 mm × 30 m, temperature: 250 ˚C) employing FID and helium as carrier gas. HPLC 
separation was performed using a Gilson system with a UV detector and Phenomenex Luna C18 
column (250 × 21.2 mm, 10 μm and 250× 4.60 mm, 5 μm). TLC was performed on glass plates 
precoated with silica gel 60 F254 and RP-18 F254 (Merck). Column chromatography was carried out 
using silica gel (Merck, 70 – 230 mesh).  
 
Extraction and purification  
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Leaves of R. brachycarpum were purchased from a farm in Gongju Korea in 2011, 
identified by Prof. MinKyun Na (College of Pharmacy, Chungnam National University), and 
deposited at the Pharmacognosy Laboratory of the College of Pharmacy, Chungnam National 
University, Daejeon, Korea (CNU00195). Dried leaves (25 kg) were extracted with MeOH (2 × 
250 L) at room temperature for one week and the extract was concentrated to yield a brownish 
slurry (6 kg). Half of the extract (3 kg) was suspended in H2O (10 L) and partitioned three times 
with n-hexane (10 L), CHCl3 (10 L), EtOAc (10 L), and BuOH (10 L) to afford four extracts 
amounting to 438, 140, 450, and 320 g, respectively. The BuOH-fraction (320 g) was further 
subjected to silica gel column VLC and eluted with CH2Cl2:MeOH:H2O (10:1→2:1:0.1) to obtain 
six fractions (Fr. B1–B6). Fr. B1 (10 g) was purified by MPLC (C18 SNAP Cartridge KP- C18-HS, 
340 g) eluting with MeOH:H2O (3:7 → 7:3) to afford seven sub-fractions (Fr. B11–B17). Fr. B14 
(1.46 g) was further purified employing preparative HPLC (Luna C18 column: 250 × 21.20 mm, 
20% MeCN, flow rate: 6 mL/min) to afford compounds 2 (26 mg, tR 40.2 min) and 5 (3.8 mg, tR 
53.6 min). Fr. B2 (22 g) was fractionated into nine fractions (B21–B29) utilizing MPLC (C18 
SNAP Cartridge KP-C18-HS, 340 g) eluting with acetone:MeOH:H2O (0:0:100→12:28:60). Fr. 
B26 (1.7 g) was subjected to silica gel MPLC (SNAP Cartridge KP-Sil, 120 g) and eluted with 
EtOAc:MeOH (98:2→90:10) to yield five fractions (B261–B265). Fr. B262 (92 mg) was 
chromatographed over a silica gel column (2 × 80 cm) and eluted with CHCl3:acetone:H2O 
(1:2:0.1) to obtain compound 1 (2 mg). Compound 4 (34 mg) was acquired from Fr. B264 (120 
mg) using a silica gel column (2 × 80 cm) eluting with CHCl3:MeOH:H2O (6.5:1:0.1). Fr. B27 (2 
g) was subjected to silica gel MPLC (SNAP Cartridge KP-Sil, 120 g) and eluted with 
CHCl3:MeOH (94:6→85:15) to yield compound 3 (159 mg).  
 
52 
 
 Rhododendroside A (1) 
Rhododendroside A (1): yellow amorphous powder; [α] 20D  = -15.4 (c 0.1, MeOH); 
HRESIMS (obsd [M+Na]+ at m/z 411.1996, calcd [M+Na]+ at m/z 411.1995). 1H NMR (methanol-
d4, 600 MHz) and 13C NMR (methanol-d4, 150 MHz) data, see Table 6. With reference to a 
previous study,90 the acid hydrolysis of compound 1 was performed as follows; the compound was 
heated in 10% HCl (1 mL) at 85 ˚C for 3 h and the residue was partitioned with EtOAc and H2O. 
The aqueous layer was evaporated to yield a residue and the residue was dissolved in anhydrous 
pyridine (100 μL) followed by the addition of 0.1 M L-cysteine methyl ester hydrochloride (100 
μL). After heating at 60 ˚C for 1.5 h, the residue was dried and trimethylsilylated with the addition 
of 1-trimethylsilylimidazole solution (500 μL), and heated at 60 ˚C for 5 min. The dried product 
was partitioned with n-hexane and H2O, and the non-polar layer was analyzed using GC. The 
monosaccharide moiety was confirmed as D-glucose based on comparison of the retention time 
with that of a D-glucose standard (tR 16.21 min) (Figure 30). 
 
GIAO NMR chemical shift calculations83,84 
All conformational searches were achieved employing Macromodel (Version 9.9, 
Schrodinger LLC.) program with “Mixed torsional/Low Mode sampling” in the MMFF force field. 
The searches were performed in the gas phase with a 50 kJ/mol energy window limit and 10,000 
maximum number of steps to completely investigate all low-energy conformers. All minimization 
processes were accomplished utilizing polak-ribiere conjugate gradient (PRCG) method, 10,000 
maximum iterations, and a 0.001 kJ (mol Å)−1 convergence threshold. C-2–C-3 and C-3–C-4 
bonds in compound 1 were constrained using a 1,000 force constant based on the associated 
coupling constants [3JH-2ax,H-3 (12.6 Hz), 3J H-3,H-4ax (12.6 Hz)]. Conformers within 10 kJ/mol of 
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each global minimum of the two diastereomers (diastereomers I and III shown in Figure 22) were 
selected for GIAO shielding constants calculation without geometry optimization employing 
Gaussian 09 package (Gaussian Inc.) at the B3LYP/6-31G(d,p) level in the gas phase. Calculated 
chemical shift values were obtained according to the following equation: δ xcalcd = (σ0 – σx)/(1 – 
σ0/106) in which δ xcalcd is the calculated chemical shift value for nucleus x (e.g., 1H or 13C), ߪ௫and 
ߪ଴are the calculated isotropic constants for nucleus x and tetramethylsilane (TMS), respectively. 
The geometry of TMS was optimized utilizing the B3LYP/6-31G(d,p) level in the gas phase for 
unbiased comparison of calculated chemical shift values with those of other molecules according 
to the original authors’ recommendation.84 These calculated chemical shift values were 
Boltzmann-averaged based on their relative MMFF94 potential energy and these averaged values 
were used for the calculation of DP4 probability employing an applet available at http://www-
jmg.ch.cam.ac.uk/tools/nmr/DP4/. All 3D images in this Chapter were rendered utilizing Pymol 
1.6.x (Schrödinger LLC.).
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Figure 26. 1H NMR (top) and 13C NMR (bottom) spectra of rhododendroside A (1) 
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Figure 27. COSY (top) and HSQC (bottom) spectra of rhododendroside A (1) 
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Figure 28. HMBC (top) and NOESY (bottom) spectra of rhododendroside A (1) 
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Figure 29. HRESIMS spectrum of rhododendroside A (1) 
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Figure 30. Identification of the glucose moiety in rhododendroside A (1) employing acid 
hydrolysis followed by GC analysis
GC chromatogram of standard D-glucose (retention time: 16.38 min)     
GC chromatogram of standard L-glucose (retention time: 17.70 min) 
GC chromatogram of the glucose  obtained from hydrolysis of rhododendroside A (1)  
(retention time: 16.21 min) 
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CHAPTER 4: SCRUTINY OF THE SOUTH AMERICAN ENDANGERED SPECIES 
DIPLOSTEPHIUM RHODODENDROIDES FOR ANTIDIABETIC DRUG LEADS 
CAPABLE OF INHIBITING PROTEIN TYROSINE PHOSPHATASE 1B 
(Some contents and figures in this chapter were reprinted from the original article published in 
Proc. Nat. Acad. Sci. U.S.A. with an appropriate citation. Permission requests have not been 
made based on the publisher policy item No. 3) 
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INTRODUCTION 
 
The genus Diplostephium comprising ~110 species is a member of the Asteraceae family, 
one of the drug-producing families addressed in the aforementioned chapters. Previous studies on 
species in the genus Diplostephium have revealed the presence of only a few chemical constituents 
including diterpenoids, diterpene lactones, phenylpropanoids,91,92 and flavonoids.93 This implies 
that the genus may be an untapped resource for providing prodrug leads. The species D. 
rhododendroides Hieron. is a rare South American shrub native to the Andes and found at altitudes 
of 3000 – 4500 meter.94,95 The genus Diplostephium is classified into three principal types based 
on the shapes of disk flowers96 and D. rhododendroides belongs to one of those types featured with 
club-shaped disk flowers merely divided into two equal lobes.   
Globally, elevated incidence of type 2 diabetes mellitus and obesity has prompted the 
search for new drug leads to alleviate metabolic diseases. Resistance to insulin and leptin is 
regarded as a common phenotype of type 2 diabetes mellitus and its related metabolic disorders.97 
In this regard, inhibition of protein tyrosine phosphatase 1B (PTP1B) has been regarded as a 
sensible approach to treat these metabolic manifestations. According to a previous study, PTP1B 
knock-out murine models demonstrated the reduced circulation of insulin, glucose, and 
triglyceride levels upon intravenous injection of insulin.98,99 This phosphatase is comprised of 435 
amino acids and the residues 177-185 construct a flexible loop called “WPD loop”. This loop is 
activated via its conformational change from “open” (inactivated) to “closed” (activated) upon 
substrate binding, leading to the formation of  a tight binding pocket for the dephosphorylation 
catalytic reaction.100 Wiesmann et al.101 discovered a novel allosteric binding site ~20 Å away from 
the catalytic pocket in PTP1B and formulated several allosteric inhibitors capable of stabilizing 
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the inactivated open conformation, which thereby hampering the closure of the WPD loop.  Owing 
to this allosteric binding site being poorly conserved among allosteric binding sites in other 
phosphatases, a specific inhibitor binding to the allosteric site of PTP1B may be developed into a 
highly selective antidiabetic agent. This is verified by the selective noncompetitive PTP1B 
inhibitor trodusquemine (MSI-1436) that has been advanced to phase I clinical trials as a potent 
hypoglycemic prodrug.101,102  
Computational approaches using a wealth of PTP1B crystal structures (~100)103 have been 
a crucial avenue for rational design and/or exploration of potent inhibitors104-107 and successfully 
applied to the identification of an oxalylaminobenzoic acid moiety as a competitive inhibitor of 
PTP1B.106,107 In particular, MD simulation could be an effective tool to search for PTP1B 
antagonists because the technique permits the investigation of dynamic changes of the WPD loop 
motility upon binding events.104,108,109 
As a follow-up study of previous research on D. rhododendroides,71 this chapter presents 
details of the isolation and structure elucidation of diplostephiosides A (1) and B (2) and their 
evaluation for PTP1B inhibitory potential. To expand a previous docking study,71 molecular 
dynamics (MD) trajectory simulation was implemented for investigation of the conformational 
state changes of the WPD loop upon allosteric binding simulation of 1, 2, and the Wiesmann’s 
allosteric inhibitor.101 
 
RESULTS AND DISCUSSION  
The molecular formula of diplostephioside A (1) was established as C26H32O13 based on 
information gleaned from a sodium adduct ion at m/z 575.1694 [M + Na]+ in HRESIMS and 13C  
NMR data (Table 7).71 The 1H and 13C NMR data of 1 (Table 7) exhibited the presence of two 
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symmetrical tetrasubstituted benzenoid moieties [δH 7.61 (H-2′, 6′), 6.85 (H-2, 6) and δC 154.4 (C-
3, 5), 149.1 (C-3′, 5′), 143.9 (C-4′), 135.8 (C-4), 134.5 (C-1), 120.1 (C-1′), 108.6 (C-2′, 6′), 105.6 
(C-2, 6)], a glucopyranosyl moiety [δH 5.75 (H-1′′) and δC 105.1 (C-1′′), 78.6 (C-2′′), 76.2 (C-4′′, 
5′′), 72.2 (C-3′′), 65.4 (C-6′′)], an ester carbonyl carbon [δC 167.1 (C-7′′)], and an E-configured 
olefinic moiety [δH 6.84 (H-7, d, J = 15.6 Hz), 6.60 (H-8, dt, J = 15.6, 4.8 Hz) and δC 129.8 (C-7), 
131.4 (C-8)].71  The HMBC correlations between the proton resonances at δH 7.61 (H-2′, 6′) and 
the ester carbonyl  carbon at δC 167.1 (C-7′′) as well as between the 3′- and 5′-methoxy protons at 
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δH 3.74 and C-3′ and 5′ at δC 149.1  revealed the presence of a syringoyl moiety (Figure 31B).71 
The second 1,2,3,5-tetrasubstituted aromatic moiety was determined to be part of the sinapyl 
alcohol unit on the basis of the HMBC correlations from the oxymethylene proton resonances at 
δH 4.59 (H2-9) to the olefinic carbon resonances at δC 131.4 (C-8) and 129.8 (C-7), from the olefinic 
proton resonances at δH 6.84 (H-7) and 6.60 (H-8) to the aromatic carbon resonances at δC 134.5 
(C-1) and 105.6 (C-2), and from the C-3 and C-5 methoxy proton resonances at δH 3.77 to the 
aromatic carbon resonances at δC 154.4 (C-3, 5) (Figure 31B).71 The syringoyl, sinapyl alcohol, 
 
(A)
(B)
Figure 31. (A) Secondary metabolites from D. rhododendroides (1–4) and (B) Key HMBC (→) 
correlations for diplostephiosides A (1) and B (2) 
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and glucosyl moieties were connected based on HMBC correlations (Figure 31B).71 The 
correlation from the anomeric proton resonance at δH 5.75 (H-1′′) to the carbon resonance at δC 
135.8 (C-4) indicated the acetalic linkage between C-1′′ of glucose and C-4 of the sinapyl alcohol 
moiety. In addition, the deshielded resonances for the diastereotopic C-6′′ protons of glucose at δH 
5.22 and 4.97, and the carbon at δC 65.4 implied an ester linkage between C-6′′ of the 
glucopyranosyl moiety and the ester carbonyl of the syringoyl moiety. This was confirmed by the 
HMBC correlation from the glucosyl C-6′′ methylene proton resonances at  δH 4.97 and 5.22 to 
the carbonyl carbon resonance of the syringoyl moiety at δC 167.1 (C-7′′) (Figure 31B).71 The 
coupling constant of the anomeric proton (H-1′′, d, J = 7.2 Hz) confirmed a β-configured glucosidic 
linkage. Acid hydrolysis followed by GC analysis of the trimethylsilylated derivative confirmed 
the presence of the D-(+)-glucopyranosyl moiety in 1 (Figure 37). Thus, the structure of the 
compound 1, diplostephioside A, was assigned as 4-[6-O-(4-hydroxy-3,5-dimethoxy-benzoyl)-β-
D-glucopyranosyloxy]-3,5-dimethoxyphenylprop-7E-en-9-ol] based upon proper 
phenylpropanoid numbering and nomenclature in contrast to those followed in reference 71. 
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Table 7.  NMR data of diplostephiosides A (1) (pyridine-d5) and B (2) (methanol-d4) 
 
1 2 
δC δH, mult. (J in Hz) δC δH, mult. (J in Hz) 
1 134.5 130.5  
2 105.6 6.85 a, s 106.1 6.80, s 
3 154.4 153.4  
4 135.8 136.8  
5 154.4 153.4  
6 105.6 6.85 a, s 106.1 6.80, s 
7 129.8 6.84 a, d (15.6) 153.5 7.42, d (16.0) 
8 131.4 6.60, dt (15.6, 4.8) 127.6 6.65, dd (16.0, 7.6) 
9 63.2 4.59, br d (4.8) 194.7 9.62, d (7.6) 
1' 120.1 119.3  
2' 108.6 7.61, s 107.0 7.14, s 
3' 149.1 147.5  
4' 143.9 141.5  
5' 149.1 147.5  
6' 108.6 7.61, s 107.0 7.14, s 
1'' 105.1 5.75, d (7.2) 102.7 5.04, d (7.6) 
2'' 78.6 4.37, m 74.2 3.56, m 
3'' 72.2 4.22, m 76.6 3.49, t (8.8) 
4'' 76.2 4.22, m 71.0 3.43, t (9.0) 
5'' 76.2 4.37, m 74.4 3.56, m 
6'' 65.4 5.22, d (11.2);4.97, dd (11.2, 6.0) 63.5 
4.53, dd (11.6, 7.6); 
4.45, dd (11.6, 2.4) 
7'' 167.1 166.4  
3, 5-OMe 57.0 3.77, s 55.4b 3.80 b, s 
3′, 5′-OMe 56.6 3.74, s 55.6b 3.81 b, s 
a Signals partially overlapped 
b Assignments may be interchanged 
 
HRESIMS analysis of diplostephiosides B (2) identified  a protonated ion at m/z 551.1745 
[M + H]+, which in conjunction with the 13C NMR data led  to its molecular formula being 
established as C26H30O13.71 The 1D NMR data (Table 7) for 2 were similar to those of 1 except 
for the NMR resonances at δH 9.62 (H-9) and δC 194.7 (C-9), diagnostic for the presence of a 
formyl functional group.71 These distinctive NMR resonances along with the difference in two 
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mass unit in 2 implied that the C-9 hydroxymethylene group of diplostephioside A (1) was replaced 
by a formyl group in 2. The HMBC correlations from the olefinic proton resonances at δH 7.42 (H-
7) and 6.65 (H-8) to the C-9 formyl resonance at δC 194.7 and the C-1 aromatic resonance at δC 
130.5, as well as from the formyl proton resonances at δH 9.62 to an olefinic carbon resonances at 
δC 127.6 (C-8) further supported the presence of a sinapyl aldehyde moiety (Figure 31).71 The β-
D-glucopyranosyl moiety of 2 was established on the basis of the coupling constant (J = 7.6 Hz) 
of the anomeric proton and acid hydrolysis followed by GC analysis of the trimethylsilylated 
derivative. The HMBC correlation of the anomeric proton resonance at δH 5.04 (H-1′′) and 
aromatic carbon resonance at δC 136.8 (C-4) revealed the connectivity between C-1′′ of glucose 
and C-4 of the sinapyl aldehyde moiety.71  The HMBC correlations of the deshielded 6′′-methylene 
proton resonances at δH 4.53  and 4.45 and the ester carbonyl carbon resonance at δC 166.4 (C-7′′) 
indicated the linkage between C-6′′ of the glucopyranosyl residue and the ester carbonyl of the 
syringoyl moiety (Figure 31B).71 Consequently, the structure of compound 2, diplostephioside B, 
was defined as 4-[6-O-(4-hydroxy-3,5-dimethoxy-benzoyl)-β-D-glucopyranosyloxy]-3,5-
dimethoxyphenylprop-7E-en-9-al, the name being generated by appropriate application of 
phenylpropanoid numbering and nomenclature.  
Compounds 3 and 4 were identified as  (+)-lyoniresinol 3α-O-β-D-glucopyranoside and 
sinapyl aldehyde, respectively, based on comparison of experimental and reported spectroscopic 
and physico-chemical data.110,111 
According to a previous study,71 compounds 1 and 2 impeded PTP1B activity with half 
maximal inhibitory concentration (IC50) values of 81.0 and 25.9 M, respectively. These anti-
PTP1B metabolites were investigated for their detailed molecular interactions with PTP1B using 
molecular docking studies, which suggested they bind to the allosteric site of the target 
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phosphatase (Figure 32).71 To enhance this preliminary docking study, the conformational changes 
of the WPD loop were investigated utilizing MD trajectory analysis monitoring the distance 
between Trp179 and Arg221 upon the binding of 1 and 2, and the Wiesmann’s allosteric inhibitor 
as a control ligand (Figure 33).101,104 The hydrogen bonding interaction between the 
aforementioned residues played an indispensable role in the activation of the WPD loop for the 
dephosphorylation catalytic reaction of PTP1B.104  Thus, the distance between the carbonyl 
oxygen of Trp179 and the nitrogen of the guanidinium moiety of Arg221 (Figure 33A, see yellow-
dotted lines) was examined using 1200 ps MD simulation (Figure 33B) upon binding of 
compounds 1 and 2, and the Wiesmann’s allosteric inhibitor to the allosteric site of PTP1B. The 
MD trajectory analysis displayed that the distances between the aforementioned residues was 
3.67–6.45, 3.50–6.15, and 3.95–6.53 Å upon simulation of the allosteric inhibition by the 
Wiesmann’s inhibitor and compounds 1 and 2, respectively. The simulated distances of the two 
atoms generated upon allosteric docking of compounds 1 and 2 were similar with that of the 
Wiesmann’s allosteric inhibitor, implying the binding of compounds 1 and 2 to the allosteric site 
stabilized and retained the inactivated (open) conformational state of the WPD loop. This 
observation indicated that their allosteric inhibition precluded the closure of the WPD loop for 
 Figure 32.71 Predicted binding poses of compounds 1 (left) and 2 (right) with key amino acid 
residues shown. Dotted lines indicate hydrogen bonds. 
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formation of a tight binding pocket to implement the catalytic reaction of PTP1B for 
dephosphorylation. The MD trajectory analysis was also in accord with previous studies101,104,105 
demonstrating the distances of the aforementioned residues to be 4.15–5.22 Å for the open 
(inactivated) conformation of the WPD loop, and 2.35–3.19 Å for the closed conformation, 
validating our in silico investigation 
on the WPD loop flexibility.   
Figure 33. (B) MD trajectory analysis 
of distance between the carbonyl 
oxygen of Trp179 and the nitrogen of 
the guanidinium moiety of Arg221. 
The measured distance is indicated as 
yellow-dotted lines in (A). The MD 
software Desmond (Schrödinger, 
LLC) was employed with reference to 
previous studies.101,104,105 The crystal 
structure was imported from the PDB 
data bank (PDB ID: 1T48), optimized, 
and minimized employing Protein 
Preparation Wizard and redrawn using 
Pymol (Schrödinger LLC.). 
Wiesmann’s inhibitor indicates the 
allosteric inhibitor co-crystallized 
with 1T48101,103 
 
 
 
CONCLUSIONS 
This chapter elaborated details on the isolation and structure elucidation of 
diplostephiosides A and B (1 and 2) from a rare South American plant species, D. 
rhododendroides. Furthermore, MD analysis of 1 and 2 based on their docking simulation 
validated that a glucosyl moiety flanked by two aromatic groups may be a suitable template that 
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could be developed into selective PTP1B allosteric antagonists. Collectively, utilization of the 
metabolites obtained from endangered and rare plant species may warrant a strong and sustained 
emphasis on their conservation. 
 
EXPERIMENTAL SECTION 
General Experimental Procedures 
See General Experiments sections in the previous chapters for routine experiment protocols. 
The GC-MS data was recorded on a Hewlett Packard GC 6890 with an HP-5 column (cross-linked 
5% phenyl methyl siloxane, 30.0 m  250 m  0.25 m) employing helium as carrier gas. 
Plant Material  
A Diplostephium rhododendroides Hieron. (Asteraceae) voucher sample was deposited in the 
National Herbarium at the Smithsonian Institution (code 0CJS1259) and the EtOH extract of the 
stems was obtained from Dr. D. Newman, Natural Products Repository, National Cancer Institute 
(NCI). 
Extraction and Isolation 
The EtOH extract (15 g) was subjected to Si gel VLC (1500 g, 40-75 µm) and eluted with a 
stepwise gradient of n-hexane/EtOAc [100:0, 75:25, 50:50, 25:75, 0:100 v/v (each 3 L)], 
EtOAc/MeOH [75:25, 50:50, 25:75, 100:0 v/v (each 3 L)], and MeOH/H2O [75:25, 50:50, 100:0 
v/v (each 3 L)] to give 12 fractions (Fr. 1 − 12). Fr. 6 (2.0 g) was further divided into 20 fractions 
(Fr. 6-1 to 6-20) using a C18 HPLC column (21.2  250 mm, 5 m) with a gradient of MeOH/H2O 
(35:65 → 60:40 v/v over 50 min, then 60:40 → 100:0 v/v for 5 min. Of these, Fr. 6-16 (99.0 mg) 
was resolved on a C18 HPLC column (10.0  250 mm, 5 m) with a linear gradient of MeCN/H2O 
(23:77 → 25:75 v/v for 60 min) to afford five sub fractions (Fr. 6-16-1 to 6-16-5). Fr. 6-16-3 was 
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further purified employing C18 HPLC [10.0  250 mm, 5 m, MeCN/H2O (17:83 v/v)] to yield 
compound 1 (tR 20 min, 8.3 mg). Purification of Fr. 6-16-5 using a C18 HPLC column (10.0  250 
mm, 5 m) with a linear gradient of MeCN/H2O (23:77 → 25:75 v/v for 60 min) afforded 
compound 2 (tR 20 min, 16.6 mg). Fr. 6-8 (15.6 mg) was chromatographed using a C18 HPLC 
column [10.0  250 mm, 5 m, MeCN/H2O (17:83 v/v) for 30 min] to yield compound 3 (tR 25 
min, 15.3 mg). Compound 4 (tR 38 min, 2.0 mg) was obtained from Fr. 6-18 (19.0 mg) employing 
a C18 HPLC column [10.0  250 mm, 5 m, MeCN/H2O (23:77 v/v) for 60 min]. 
Diplostephioside A (1): white amorphous powder; []25D −15 (c 0.2, MeOH); UV (DAD) max 
265.8 nm; 1H and 13CNMR see Table 1; HRESIMS m/z: 575.1694; [M + Na]+ (Calcd. for 
C26H32Na1O13: 575.1735)71 
Diplostephioside B (2): white amorphous powder; []25D −28 (c 0.2, MeOH); UV (DAD) max 
292.4, 315.6 nm; 1H and 13C NMR see Table 1; HRESIMS m/z: 551.1745 [M + H]+ (Calcd. for 
C26H31O13: 551.1765)71 
Carbohydrate Analysis90  
Compound 1 (1 mg) was dissolved in 0.5 mL of 1 N HCl, heated at 90 C for 2 h, and partitioned 
with EtOAc and H2O (3  1 mL). The aqueous layer was neutralized with Ag2CO3 and centrifuged. 
The dried supernatant was dissolved in anhydrous pyridine (1 mL) and 0.1 M L-cysteine methyl 
ester hydrochloride in pyridine (2 mL) was added. The mixture was kept at 60 C for 1 hr. After 
the reaction mixture was dried in vacuo, the residue was trimethylsilylated with 1-
trimethylsilylimidazole (0.5 mL) at 60 C for 5 min. The resulting mixture was partitioned between 
n-hexane and H2O (3  1 mL) and the n-hexane fraction was analyzed utilizing a GC column (HP-
5ms, 5% phenyl 95% methyl polysiloxane, 30.0 m  250 m  0.25 m). The injector temperature 
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was set at 260 C and the GC oven temperature was kept at 100 C for 1 min and increased to 280 
C at a rate of 20 C/min using helium as carrier gas. The retention times of the standard sugars 
were as follows: D-glucose (tR 10.84 min) and L-glucose (tR 10.95 min). In the hydrolysates of 1, 
only D-glucose (tR 10.83 – 10.85 min) was detected (Figure S14). 
PTP1B Assay 
PTP1B (human, recombinant) was purchased from BIOMOL International LP (Plymouth 
Meeting, PA). The enzyme activity was evaluated utilizing pnitrophenyl phosphate (pNPP), as 
described previously.112 To each of 96 wells in a microtiter plate (final volume: 100 L) was added 
2 mM pNPP and PTP1B (0.05  0.1 g) in a buffer containing 50 mM citrate (pH 6.0), 0.1 M 
NaCl, 1 mM EDTA, and 1 mM dithiothreitol with or without the test compounds. After incubation 
at 37C for 30 min, the reaction was quenched with 10 M NaOH. The amount of pnitrophenol 
was evaluated by measuring the absorbance at 405 nm. The non-enzymatic hydrolysis of 2 mM 
pNPP was adjusted assessing the increase in absorbance at 405 nm obtained in the absence of 
PTP1B enzyme. 
Molecular Dynamics (MD) Simulation  
All MD simulations were performed using Desmond ver. 3.0 (Schrödinger LLC.) based on 
protocols of previous PTP1B MD studies.105,113 Compounds 1 and 2, and 1T48 employed for 
previous docking studies71,103 were minimized and solvated under the OPLS2005 force field with 
the explicit simple point charge (SPC) water model. The systems were neutralized by the addition 
of six sodium ions to replace SPC water molecules. MD simulations (1.2 ns) were carried out 
under 300 K and 1.0 atm. The coordinates were saved with every 1.2 ps of energy and 4.8 of 
trajectory.  
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Figure 34. 1H (top) and 13C (bottom) NMR spectra (pyridine-d5) of diplostephiosides A (1) 
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Figure 35. DQF-COSY and heteronuclear multiple-quantum correlation spectroscopy (HMQC) 
spectra (pyridine-d5) of diplostephiosides A (1) 
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Figure 36. HMBC and HRESIMS spectra of diplostephiosides A (1) 
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Figure 37. Overlaid GC spectra of trimethylsilylated glucosyl moiety of 1 and chiral glucose 
standards 
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Figure 38. 1H (top) and 13C (bottom) NMR spectra (methanol-d4) of diplostephiosides B (2) 
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Figure 39. COSY (top) and HMQC (bottom) spectra of diplostephiosides B (2) 
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Figure 40. HMBC and HRESIMS spectra of diplostephiosides B (2)
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PART II: SYNTHETIC STRATEGY FOR PARTIAL SYNTHESIS OF SPONGE-
DERIVED CYTOTOXIC DRUG PROTOTYPES AND STEREOSTRUCTURE OF 
BRCA1-IRIS INHIBITORY PEPTIDE EXHIBITING POTENT IN VIVO CYTOTOXIC 
ACTIVITY ON TRIPLE-NEGATIVE BREAST CANCER AND 
 
CHAPTER 5 
N-DEMETHYLATED MAKALUVAMINE A, A VERSATILE INTERMEDIATE FOR THE 
SYNTHESIS OF PYRROLOIMINOQUINONE-BASED CYTOTOXIC ALKALOIDS 
 
CHAPTER 6 
CHARACTERIZATION OF THE 3D STRUCTURE OF BRCA1-IRIS INHIBITORY PEPTIDE 
EMPLOYING THE ENSEMBLE OF A HIGH-FIELD NMR STUDY AND IN SILICO 
METHODS 
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CHAPTER 5: N-DEMETHYLATED MAKALUVAMINE A, THE VERSATILE 
INTERMEDIATE FOR SYNTHESIS OF PYRROLOIMINOQUINONE-BASED 
CYTOTOXIC ALKALOIDS
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INTRODUCTION 
 
Pancreatic cancer has been recognized as a major cause of death in the West along with 
breast cancer that will be addressed in Chapter 6.  In 2015, an estimated 48,960 people in the US 
will be diagnosed  with pancreatic cancer and about 20,710 will die from the serious disease.114 
These statistics render the malignancy to be the 4th leading cause of death from cancer in the 
US,115 despite significant reductions in deaths and diagnoses of many other cancers.  
Marine organisms harvested from global bodies of water have been validated as enriched 
resources for providing diverse and potent anticancer drug leads.116 This is evidenced by the first 
anticancer drug to reach the market ecteinascidin-743 (ET-743/trabectedin) from the Caribbean 
tunicate Ecteinascidia turbinate,117 a cytotoxic cyclic depsipeptide, didemnin B from the tropical 
Trididemnum solidum118 and kahalalide F from the herbivorous Hawaiian opisthobranch Elysia 
rufescens and its prey Bryopsis spp.,119 halichondrin B from the Japanese sponge Halichondria 
okadai120 which was modified into the recently FDA-approved anticancer drug, eribulin 
mesylate,121 and pyrroloiminoquinones such as the discorhabdins and makaluvamines, from 
diverse sponge sources worldwide, showing broad-spectrum antiproliferative effects and capable 
of inhibiting topoisomerase II, respectively.122 Despite the extensive global investigations of 
marine resources during the last few decades,116 the Aleutian Islands and invertebrate communities 
have been underutilized in investigation of antineoplastic leads presumably because of limited 
access. Consequentially, some marine environments in the Aleutian Islands remain unexplored, 
which may hold a promise for providing novel and prospective prototypes for anticancer 
chemotherapy. During our research group’s sponge collection conducted in deep waters off the 
Aleutian Islands, more than 150 marine invertebrates were harvested and subjected to various 
bioassay screenings to search for antiproliferative pharmacophores.123 Among the collected 
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diverse sponge materials, Latrunculia spp. produced discorhabdin X (unpublished) possessing 
intriguing ring systems based on a pyrroloiminoquinone architecture122 and exhibiting selective 
cytotoxic activities in breast, brain, and pancreatic cancer cell lines (Table 8).  
Table 8. Discorhabdin X and zones of inhibition (mm) against a wide range of cancer cell types. 
DMSO and ecdysone are employed as negative controls and discorhabdin A and karlotoxin 2 as 
positive controls. 
Compound Conc. (mg/mL) 
L1210 
(m
urine leukem
ia) 
Colon 38 
(m
urine colon cancer) 
CFU-G
M
 
(hum
an hem
atopoietic 
progenitor cell) 
H-116 
(hum
an colon cancer) 
H-125 
(hum
an lung cancer) 
M
CF-7 
(hum
an breast cancer) 
LNCaP 
(hum
an prostate cancer) 
OVCAR-5 
(hum
an ovarian cancer) 
U251N 
(hum
an brain tum
or) 
M
DA-M
B-231 
(hum
an breast cancer) 
PANC-1 
 (pancreatic cancer) 
CCRF-CEM
 
(hum
an leukem
ia) 
DMSO  0 0  0 0 0 0 0 0 0 0  
Ecdysone 2 0 0  0 0 0 0 0 0 0 0  
 
Discorhabdin X  
 
2 950 >1000  >1000         
1/4 700 >1000 >1000 950 >1000 >1000  900 >1000 >1000  900 
1/16 500 900 >1000 600 900 >1000 1000 700 850 800 >1000 750 
1/64 250 450 750 250 400 600 500 350 700 500 650 350 
Karlotoxin 2 2 150 200  200 100 200 400 200 150 200 200 100 
Discorhabdin A 
2 1000 750  >1000         
1/4 300 800 >1000 900 950 800  700 300 1000 450 450 
1/16 250 700 300 500 750 600 500 500 300 500 150 100 
1/64     400 350 250 200 200 300 100 50 
The difficulty of developing prodrugs from marine invertebrates is evident because those materials 
are generally unculturable, which implies that the marine-derived secondary metabolites should 
be extracted and purified from specimens harvested by costly endeavors.116 This poses a serious 
challenge to an adequate supply of marine natural products, which is a prerequisite for determining 
their clinical potential in vivo. Even though synthetic approaches have played a role in resolving 
the supply strain, large-scale synthesis demands a significant amount of time and resources, and 
often fail in generating an appropriate amount of target compounds. Thus, it is of great importance 
to fashion a viable synthetic route where each step comprising the synthetic strategy is well-
established, and cost-effective starting materials and reagents are utilized.  
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 Among the numerous 
pharmacophores identified from 
marine communities, 
pyrroloiminoquinone-based alkaloids 
such as discorhabdins and 
makaluvamines, briefly mentioned in 
the Introduction, have been 
recognized as a prospective 
antineoplastic scaffold due to the 
highly fused planar core structure.122 There have been previous attempts to synthesize cytotoxic 
pyrroloiminoquinone alkaloids (Scheme 2).  The core tricyclic indole architectures were prepared 
via condensation of tryptamines with the quinone residue,124-127 or cyclization of 4-
aminoindole,128-131 4-chlorotryptamine,132 or 3-(azidoethyl)indole functionalities.133,134 However, 
some of those strategies were developed based on costly starting materials, more than 10 reaction 
steps, and relatively small reaction scales (see Scheme 2 for details). This makes it impractical that 
those approaches are applied for a large scale synthesis of a marine-derived prodrug to address the 
supply strain. This chapter delineates the development of a practical and scalable synthetic 
approach (Hamann’s group approach in Scheme 2) employing inexpensive starting materials with 
a large scale (230 mmol), and relatively short and straightforward reaction steps (eight steps) with 
stable intermediates aiming at the synthesis of a sufficient amount of the versatile intermediate I 
Scheme 1. The versatile intermediate I (N-demethylated 
makaluvamine A) for the synthesis of 
pyrroloiminoquinone-based cytotoxic alkaloids
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for discorhabdin X and the related pyrroloiminoquinone-based cytotoxic alkaloids (Scheme 1).  
  
RESULTS AND DISCUSSION  
Unlike the previous protocols for synthesis of pyrroloiminoquinones (Scheme 2), the current 
strategy in this chapter employs a tryptamine framework in I as the key intermediate. In order to 
cost-effectively synthesize it, a one-pot synthesis approach utilizing palladium-catalyzed 
annulation of o-iodoaniline 2 and aldehyde 5 was employed.135 With reference to reported 
procedures, commercially available aniline 1 was iodinated employing iodine monochloride in a 
O
MeO
N
MeO
OMe
COOH
MeO
OMe
N
NH2
PG
OTs
N
PG
A) Indole Approach
MeO
X
MeO
O
N
O
PG
NHR
O
MeO
N
N
PG
Kita's group (14 steps, 5.3 mmol, 3.8%)141,142
Cava's group (13 steps, 128 mmol, 8.9%)143
Heathcock's group (11 steps, 31 mmol, 11.8%)
expensive starting material144
MeO
OMe
NHPG
NHR
MeO
OMe
N
NH2
PG
O
O
OMe
MeO
HN
N
PG
O
O
MeO
N
N
PG
Lown's group (8 steps, NA, 3.4%)147
Yamamura's group (14 steps, 10 mmol, 8.8%)
expensive starting material145,146
MeO NH MeO N
Cl
PG
NH2
MeO
HN
N
PG O
MeO
N
N
PG
Iwao's group (13 steps, 51 mmol,11%)149
MeO
OMe
N
H MeO
OMe
N
PG
N3
O
MeO
N
N
H
Kita's group (seven steps, 0.5 mmol, 29%)
expensive starting material150,151
B) Tryptamine Approach (discussed in this chapter)
NH2
OMe
MeO
N
H
OMe
MeO
NH2
MeO
OMe
N
PG
N3
O
MeO
N
N
Hamann's group (eight steps, 230 mmol, 2%)
White's group (11 steps, 29 mmol, 2.5%)148
PG
Scheme 2. Previous protocols for the synthesis of pyrroloiminoquinones. Part of this scheme was 
adopted with permission from Hu, J.-F.; Fan, H.; Xiong, J.; Wu, S.-B. Chem. Rev. 2011, 111, 5465-
5491. Copyright 2011 American Chemical Society. Reaction steps, scales, and overall yields for 
each synthetic approach are shown in parentheses; PG: Protecting Group; NA: Not Available  
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biphasic solution to generate 6-iodo-2,3-dimethoxyaniline (2) (70%, 66 mmol-scale) (Scheme 3) 
for the Pd-catalyzed coupling reaction.136 Using Dess–Martin periodinane (DMP) oxidation, the 
other aldehyde (5) partner was prepared from 4-phtalimidobutanol 4 (60%, 36 mmol-scale)137,138 
that was synthesized simply by heating a mixture of phthalic anhydride and   4-aminobutanol 3 
(quantitative, 230mmol-scale) (Scheme 3).139 
The coupling reaction was implemented with 2 and 5 via the intramolecular Heck reaction 
catalyzed by the relatively inexpensive palladium source Pd(OAc)2 (50%, 10.5 mmol-scale)  
ICl
NH2
OMe
MeO NH2
OMe
MeO
I
2
ether/Na2CO3
1
70%
HO
NH2 N
O
O
OH
N
O
O
O
3 4 5
phthalic anhydride
140 °C
quantitative
DMP
DCM/0 °C to r.t.
60%
Scheme 3. Preparation of coupling partners for the generation of dimethoxytryptamine via pd-
catalyzed annulation 
Scheme 4. Pd-catalyzed cyclization via intramolecular Heck reaction and its mechanism. Pd: 
Pd(OAc)2, DABCO: 1,4-diazabicyclo[2.2.2]octane 
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(Scheme 4) to generate 
N-protected 6,7-
dimethoxytryptamine 
6.135,140 The Pd-
catalyzed reaction 
should be performed 
carefully in terms of 
the purity of the 
coupling partners, 
reaction concentrations, and an accurate amount of the catalyst used since the reaction was 
involved with an intermolecular reaction to produce enamine and an intramolecular reaction to 
generate the pyrrole functionality (Schemes 4 and 5). Indeed, residual ICl used to generate 2 
rapidly oxidized phthalamic aldehyde 5 into its corresponding carboxylic acid 5a (Scheme 5). This 
unexpected oxidation was also effected by residual oxygen in dimethylformamide (DMF), which 
stresses the necessity of the solvent being rigorously degassed for the annulation reaction.  
Moreover, an excessive amount of Pd(OAc)2 led to the dehalogenation of 2 to form 2a and this 
deiodinated product subsequently reacted with 5a, leading to a significant reduction in yield of the 
Pd-catalyzed reaction 
(Scheme 5). The 
phthalimide-protected 6 
was deprotected  
utilizing 85% hydrazine 
monohydrate to obtain 
Scheme 5. Side reactions dropping the yield of the palladium-
catalyzed cyclization reaction 
Scheme 6. Deprotection of the phthalimide group and successive 
formation of azide 8 
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6,7-dimethoxytryptamine 7 (60%).140 Next, Cu2+-catalyzed azido group transfer using 
trifluoromethanesulfonyl azide (TfN3) was implemented to convert amine 7 to azide 8 (50%)141 
(Scheme 6) that would play a key role in constructing a pyrroloiminoquinone template in later 
steps.  This azido transferring strategy, which has been predominantly used in aminosugar 
synthesis, was also applicable for generating a target azide from a terminal amino group 
comprising a tryptamine moiety, which verifies the substrate tolerance of such a reaction 
application. 
The indole alkaloid bearing an ethylazido side chain 8 was used to attempt cyclization into  
pyrroloiminoquinone 9 utilizing the hypervalent iodine (III) reagent 
[bis(trifluoroacetoxy)iodo]benzene (PIFA) activated by trimethylsilyl trifluoromethanesulfonate 
(TMSOTf) in a mixture of (CF3)2CHOH (1,1,1,3,3,3-hexafluoroisopropanol, HFIP) and H2O.133 
The reaction resulted in complex mixtures presumably because of side reactions occurring with 
the activated PIFA at the nucleophilic centers in 8, i.e., N-1, C-2, and C-3 as discussed in previous 
studies.133,142 Alternatively, the N-1 position of indoles was protected with electron-withdrawing 
groups including an acetyl  group (9, 75%) and treated with the activated PIFA in a mixture of 
HFIP and H2O (50:1) to establish the formation of the corresponding pyrroloiminoquinone 10 as 
 
Scheme 7. Activated PIFA-mediated formation of the indole-based tricyclic structure followed 
by transamination for synthesis of the end product I. t-BuOK: potassium tert-butoxide 
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found in previous studies (50%) (Scheme 7).133,143 The transamination approach, which was 
employed for such transformation from N-methylated 10 to makaluvamine A, was adopted to 
convert 10 to I, the end product (60%) (Scheme 7).144 
Even though some reaction steps in this chapter were validated to be scalable and versatile 
with diverse substrates, those protocols were not successful in terms of the overall yield (2%) as 
compared to a similar synthetic scheme developed by Kita’s group to generate the key intermediate 
10 (Scheme 8, 29%).143 Thus, the Kita’s protocols are currently attempted to be reproduced and 
optimized to synthesize 8. The commercially available starting material 11145 was treated with 
oxalyl chloride in dry Et2O to synthesize 12 (85%), which was reduced into 13 using LiAlH4 in 
dry THF (50%). The current yields are lower than the reported ones, which implies that 
optimization of the currently performed reactions is necessary. 
CONCLUSION AND FUTURE WORK 
This chapter aimed to establish a scalable synthetic protocol comprised of well-established 
synthesis protocols with low-priced starting materials to provide a sufficient amount of the 
versatile intermediate I. A large amount of pyrroloiminoquinone I may resolve the supply strain 
of pyrroloiminoquinone-based antineoplastic alkaloids such as discorhabdins, makaluvamines, 
and discorhabdin X from deep waters off the Aleutian Islands to investigate their antineoplastic 
potentials in vivo. Even though the current yields and scales of some steps need to be improved 
for a large-scale synthesis of I, this chapter may serve as a stepping stone for the design of a cost- 
and time-effective synthetic strategy for the challenging synthesis of the indole-based tricyclic 
Scheme 8. Alternative synthetic route for the generation of 8; Yields in parentheses are the 
reported ones.143 
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architectures and further examination of their therapeutic potentials for control of various cancer 
types and related complications. Besides, further reproducing efforts and optimization of Kita’s 
approach will be required.  
EXPERIMENTAL SECTION 
General Experiments  
See General Experiments sections in the previous chapters for routine experiment protocols. 
Chemicals were purchased from Sigma-Aldrich (St. Louis, MO), Fischer Scientific (Pittsburgh, 
PA), J & W PharmLab (Levittown, PA), Oakwood Chemical (West Columbia, SC), and 
Waterstone Technology (Carmel, IN).   
Synthesis Details 
6-Iodo-2,3-dimethoxyphenylamine (2).136  
A biphasic mixture composed of 440 mL of ether and 60 mL of saturated Na2CO3 was prepared 
and 10.0 g (66 mmol) of 2,3-dimethoxyaniline was stirred in the dark. To this biphasic mixture 
was added slowly 17 g (108 mmol) of iodine monochloride in 72 mL of ether. The reaction mixture 
was stirred for 4 h and the layers were separated using a separation funnel. The ether layer was 
washed five times with saturated Na2SO3 or Na2S2O3 to thoroughly remove residual iodine 
monochloride and the combined ether layer was dried over anhydrous MgSO4 and concentrated. 
The residue was purified using gravity silica gel chromatography to give 13 g (70%) of 1 as a 
yellow solid; 1H NMR (400 MHz, CDCl3) δH 3.83 (s, 3H), 3.84 (s, 3H), 4.25 (brs, 2H), 6.19 (d, 
1H, J = 9.0 Hz), 7.31 (d, 1H, J = 9.0 Hz); 13C NMR (100 MHz, CDCl3) δC 56.0, 60.1, 74.0, 
104.4, 133.3, 135.4, 141.8, 153.2. 
4-Phthalimidobutanol (4).139 
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A mixture of phthalic anhydride (36 g, 240 mmol) and 4-aminobutanol (20 g, 240 mmol) was 
heated to 145 °C. Nitrogen gas was streamed to remove water vapor. After cooling to r.t., the 
reaction residue was dried and the product was obtained as a pale yellow oil (quantitative); 1H 
NMR (400 MHz, CDCl3) δH 1.5 (p, 2H, J = 6.0 Hz), 1.6 (p, 2H, J = 7.6 Hz), 3.5 (t, 2H, J = 6.5 
Hz), 3.7 (t, 2H, J = 7.2 Hz), 7.6 (m, 2H), 7.8 (m, 2H); 13C NMR (100 MHz, CDCl3) δC 24.9, 29.7, 
37.6, 61.6, 123.0, 131.8, 133.8, 168.3. 
4-Phthalimidobutanal (5).137,138 
Compound 4 (5 g, 23 mmol) was dissolved in 50 mL of dichloromethane (DCM) in an ice bath 
and Dess-Martin periodinane (15 g, 33 mmol) was added to the solution under argon. The reaction 
mixture was stirred overnight, diluted with DCM, and added with saturated Na2S2O4 and NaHCO3. 
The organic layer was dried over MgSO4 and concentrated.  The residue was chromatographed 
over gravity column chromatography to furnish 5 (60%) as a white power. 1H NMR (400 MHz, 
CDCl3) δH 1.9 (p, 2H, J = 7.0 Hz), 2.5 (t, 2H, J = 6.9 Hz), 3.7 (t, 2H, J = 7.0 Hz), 7.6 (m, 2H), 7.8 
(m, 2H), 9.7 (s); 13C NMR (100 MHz, CDCl3) δC 21.0, 37.0, 40.9, 123.1, 131.8, 133.9, 168.2, 
200.9. 
3-(2-Phthalimidoethyl)-6,7-dimethoxyindole (6).140 
A mixture of 2 (3 g, 11 mmol), 5 (2.3 g, 11 mmol), and DABCO (3.7 g, 33 mmol) in dry 
dimethylformamide (DMF) (55 mL) was degassed using freeze-thaw-pump technique. Pd(OAc)2 
(120 mg, 0.55 mmol) was added to the reaction mixture and it was heated at 85 ˚C for 12 – 24 h. 
The reaction was monitored using TLC and additional palladium source was added to completely 
consume 5. Upon the completion of the reaction, the mixture was cooled to room temperature and 
diluted with water. The aqueous layer was extracted with EtOAc and the combined organic phases 
91 
 
were washed with brine, dried using (MgSO4), and evaporated under reduced pressure. Purification 
of crude product by gravity column chromatography provided the desired product (50%) and 
starting material 2 (10%). 1H NMR (400 MHz, CDCl3) δH 3.1 (t, 2H, J = 7.8 Hz), 3.9 (s, 3H), 4.0 
(s, 3H), 4.0 (t, 2H, J = 7.1 Hz), 6.86 (d, 1H, J = 7.0 Hz), 7.0 (s, 1H), 7.4 (d, 1H, J = 7.0 Hz), 7.7 
(m, 2H), 7.8 (m, 2H); 13C NMR (100 MHz, CDCl3) δC 24.5, 38.4, 57.5, 60.8, 108.3, 112.7, 113.8, 
121.7, 123.2, 124.2, 130.8, 132.2, 133.9, 134.5, 147.2, 168.3. 
6,7-Dimethoxytryptamine (7).140 
To a solution of 6 (900 mg, 0.4 mmol) in 90 mL of MeOH, 60% hydrazine monohydrate (9 mL, 
180 mmol) was added and the mixture was proceeded for 2 h. After addition of saturated aqueous 
NaHCO3 solution (100 mL), the solvent was evaporated and the aqueous phase was extracted 
sufficiently with EtOAc (8 × 20 mL). The collected organic phase was dried over MgSO4 and 
evaporated under reduced pressure, and the resultant residue was chromatographed on gravity 
silica column chromatography using a mixture solvent (MeOH:CH2Cl2:NH4OH = 10:100:1) to 
afford a light yellow oil 7 (28 mg) (60%). 1H NMR (400 MHz, CDCl3) 2.8 (t, 2H, J = 6.2 Hz), 3.0 
(br t, 2H),  3.9 (s, 3H), 3.9 (s, 3H), 6.8 (d, 1H, J = 8.2 Hz), 6.9 (s, 1H), 7.2 (d, 1H, J = 8.4 Hz); 13C 
NMR (100 MHz, CDCl3) 28.6, 41.6, 57.1, 107.5, 112.9, 113.4, 121.9, 124.2, 130.7, 134.2, 146.6. 
3-(2-Azidoethyl)-6,7-dimethoxyindole (8).141 
A triflyl azide solution was freshly prepared with reference to a previous study.141 Compound 7 
(200 mg, 0.93 mmol) was dissolved in 3 mL of H2O and treated with potassium carbonate (192 
mg, 1.39 mmol) and CuSO4 hydrate (1.4 mg., 8.8 mmol). To this solution was added MeOH (6 
mL) and the triflyl azide solution. Additional MeOH was added for homogeneity of the reaction 
mixture and the reaction mixture was stirred for 18 h. The mixture was filtered through cotton, 
extracted with DCM three times and the organic layer was concentrated. The residue was applied 
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to gravity silica column chromatography to obtain compound 8 (50%) as a pale yellow oil. 1H 
NMR (400 MHz, CDCl3) 3.0 (t, 2H, J = 7.2 Hz), 3.6 (t, 2H),  3.9 (s, 3H), 4.0 (s, 3H), 6.9 (d, 1H, J 
= 8.5 Hz), 7.0 (br s, 1H), 7.2 (d, 1H, J = 8.4 Hz); 13C NMR (100 MHz, CDCl3) 25.1, 51.6, 57.5,60.8, 
108.3, 112.5, 113.5, 122.0, 124.0, 130.9, 134.6, 147.2. 
1-Acetyl-3-(2-azidoethyl)-6,7-dimethoxyindole (9).143 
A solution of 8 (0.50 mmol) in dry THF (5.0 mL) was added dropwise to a stirred suspension of 
potassium t-butoxide (1.0 mmol) in dry THF (1.25 mL) under argon at an ice bath and stirred at 0 
°C for 1 h. Acetyl chloride was added to the solution at 0 °C and the reaction mixture was stirred 
for overnight at r.t. The mixture was quenched with H2O and extracted with CH2Cl2. The organic 
layer was dried over MgSO4, evaporated, and subjected to gravity column chromatography to give 
9 (75%). 1H NMR (400 MHz, CDCl3) 2.6 (s, 3H), 2.8 (t, 2H, J = 7.2 Hz), 3.5 (t, 2H),  3.9 (s, 3H), 
3.9 (s, 3H), 6.9 (d, 1H, J = 8.5 Hz), 7.1 (d, 1H, J = 8.4 Hz), 7.3 (br s, 1H); 13C NMR (100 MHz, 
CDCl3) 24.6, 25.2, 50.5, 56.9,60.7, 110.4, 113.7, 117.5, 124.6, 127.5, 128.9, 137.8, 151.3, 168.7. 
7-Methoxy-3,4-dihydropyrrolo[4,3,2-de]quinolin-8(1H)-one (10).133,143 
To a stirred solution of 9 (0.20 mmol) in HFIP/H2O (10 mL:0.20 mL), TMSOTf (0.500 mmol) 
was added dropwise at 0 °C under argon and PIFA was added successively (0.24 mmol). After 
stirring for 1.5 h at 0°C, the mixture was quenched with NaHCO3 and the solvent was evaporated. 
The residue was extracted with CH2Cl2 and concentrated to be used for the next reaction without 
purification due to its structural instability. 1H NMR (400 MHz, CDCl3) 2.8 (t, 2H, J = 8.3 Hz), 
3.8 (s, 3H), 4.2 (t, 2H, J = 8.1 Hz), 6.1 (s, 1H), 6.9 (s, 1H) 
7-Amino-3,4-dihydropyrrolo[4,3,2-de]quinolin-8(1H)-one (I).144 
A mixture of 10 (113 mg, 0.5 mmol) and NH4Cl (270 mg) in MeOH (25 mL) was stirred r.t. 
overnight. The mixture was concentrated and the resultant residue was purified utilizing gravity 
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silica gel (CH2Cl2/MeOH/NH4OH = 80:20:1 → 70:30:1) to garner I (60%). The purified 
compounds was treated with TFA in MeOH, resulting in the formation of its corresponding TFA 
salt. 1H NMR (400 MHz, methanol-d4) 2.9 (t, 2H, J = 7.5 Hz), 3.8 (t, 2H, J = 7.7 Hz), 5.7 (s, 1H), 
7.1 (s, 1H). 
6, 7-Dimethoxy-3-(2-hydroxyethyl)indole (13)143 
To a solution of 6,7-dimethoxyindole (11) (100 mg, 0.564 mmol) in dry Et2O (10 mL) a solution 
of oxalyl chloride (0.064 mL, 0.734 mmol) in Et2O (8 mL) was added dropwise under argon at 0 
°C and stirred for 2 h at 0 °C. EtOH (0.12 mL) was added to the reaction mixture at 0 °C and this 
was stirred for 3 h r.t. NaHCO3 was added to quench the reaction and the mixture was extracted 
with EtOAc. The organic layer was evaporated and proceeded to the next step without purification 
to provide 12 (85%). 1H NMR (400 MHz, CDCl3) 1.3 (t, 3H, J = 7.2 Hz), 3.9 (s, 3H), 3.9 (s, 3H), 
4.4 (q, 2H, J = 7.2 Hz), 7.0 (d, 1H, 8.9 Hz), 8.0 (d, 1H, 8.9 Hz), 8.4 (br d, 1H); 13C NMR (100 
MHz, CDCl3) 14.0, 56.9, 61.1, 62.1, 111.0, 114.6, 117.4, 121.8, 130.8, 134.4, 137.2, 148.6, 162.8, 
178.2.  A solution of 12 (70 mg, 0.25 mmol) in THF (1 mL) was added dropwise to a suspension 
of LiA1H4 (98 mg, 2.5 mmol) in THF (4 mL) under an argon atmosphere at 0 °C, and the mixture 
was stirred in the ice bath for 20 mins. The mixture was carefully quenched with EtOAc, MeOH. 
and brine. After filtration was performed through Celite, the filtrate was concentrated in vacuo. 
The residue was dissolved with EtOAc and then evaporated to give pure 6 (1.13 g, quant) as a 
colorless oil. 13C NMR (100 MHz, CDCl3) 28.7, 57.4, 60.8, 62.5, 108.1, 112.4, 113.7, 122.3, 124.1, 
130.9, 134.4, 147.1. 
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Figure 41. 1H and 13C NMR spectra of 2 (CDCl3)   
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Figure 42. 1H and 13C NMR spectra of 4 (CDCl3) 
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Figure 43. 1H and 13C NMR spectra of 5 (CDCl3) 
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Figure 44. 1H and 13C NMR spectra of 6 (CDCl3) 
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Figure 45. 1H and 13C NMR spectra of 7 (CDCl3) 
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Figure 46. 1H and 13C NMR spectra of 8 (CDCl3) 
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Figure 47. 1H and 13C NMR spectra of 9 (CDCl3) 
101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48. 1H spectra of 10 (CDCl3) and I (methanol-d4) 
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Figure 49. 1H and 13C NMR spectra of 12 (CDCl3) 
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Figure 50. 13C NMR spectra of 13 (CDCl3) 
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CHAPTER 6: CHARACTERIZATION OF THE 3D STRUCTURE OF BRCA1-IRIS 
INHIBITORY PEPTIDE EMPLOYING THE ENSEMBLE OF A HIGH-FIELD NMR 
STUDY AND IN SILICO METHODS 
 
INTRODUCTION 
 
Breast cancer is the second most diagnosed cancer in women in the US146 and the estimated 
new cases and deaths are 232,670 and 40,000, respectively, for 2014,147 imposing a serious burden 
on health care communities and resources. The development of cytotoxic agents targeting breast 
cancer is challenging because the malignant disease is diverse with various histological and 
molecular subtypes carrying distinctive biological properties, resistance, and responses to 
anticancer therapies.148 The most invasive breast cancer subtype is triple-negative breast cancer 
(TNBC) characterized by a lack of estrogen and progesterone receptors, and human epidermal 
growth factor receptor 2  amplification.149 These malignant features lead to conventional cytotoxic 
agents, including  tamoxifen and herceptin, being ineffective for cancer treatment.150 The TNBC 
comprises ~15% of all the cases and shares many common oncogenic features with BRCA1-
associated tumors.149 Despite high susceptibility of TNBC to neo-adjuvant chemotherapy utilizing 
paclitaxel, invasive breast cancer is prone to recurring upon visceral metastases.150 To date, there 
is no comprehensive clinical strategy alleviating TNBC and its associated metastases, raising an 
urgent need for the establishment of effective antiproliferative strategies for mitigation of this 
aggressive breast cancer.  
105 
 
BRCA1-IRIS (IRIS) is an oncogenic 1399 amino acid and expressed from the identical 
locus as the tumor suppressor gene BRCA1.150-152 The up-regulated IRIS expression facilitates the 
growth of breast tumors and circumvents apoptosis by curbing p53 activity and/or activating the 
Akt pathway, and ultimately inducing survivin expression.153 This collectively results in the 
resistance of the malignant cells to current chemotherapeutic strategies including etoposide, 
ionizing or UV-radiation, and oxidative stress.153 The elevated expression of IRIS is typically 
observed in TNBC cell lines and tumor cells particularly lacking the expression of the tumor 
suppressor BRCA1.153 A recent study corroborates that IRIS employs its intron 11 peptide to 
interact with other unknown proteins (X factors) in the oncogenic functions.154 Based on this study, 
a mimetic IRIS-inhibitory peptide (IRIS-IP), composed of the oncogenic intron sequence attached 
to a nuclear penetrating signal, was formulated to prevent the formation of tumorigenic complex 
(Figure 51).154  
RESULTS AND DISCUSSION 
Figure 50. The schematic representation of the anti-oncogenic mechanism of IRIS inhibitory 
peptide (A) and its sequence (B). X stands for X factors. The figure was obtained from Nature 
Publishing Group with a permission via Rightslink® (License No. 3584830592805) 
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The stereostructure of a cytotoxic molecule is crucial in fully examining the underlying 
antineoplastic mechanism and formulating strategies to enhance the activity. To achieve this goal, 
it is essential to acquire an NMR solution structure employing a wide array of NMR pulse 
programs such as TOCSY,155 COSY,156 NOESY,157 1H-13C and 1H-15N HSQC,158 and recently 
developed long range (LR)-HSQMBC.159 To complement biased and ambiguous structural 
elucidation processes of macromolecules using NMR spectroscopy,160 homology modeling of 
IRIS-IP with its sequence (Figure 51) was implemented with reflection of spatial and dihedral 
information deduced from NMR data. Preliminary homology modeling was conducted using 
Prime® (Schrodinger LLC.) and successfully built in chain A of rat metallophosphodiesterase 
Mpped2a (PDB ID: 3RL3, resolution 1.42 Å) (Figure 52). The identity score between the two 
protein structures calculated by the computational software was relatively low (28.1/100), 
implying a unique folding pattern of IRIS-IP.  Spatial distances, vitally important in elucidation of 
3D structures of macromolecules, were acquired utilizing NOESY spectra recorded in DMSO-d6 
with 5 or 10 % of trifluoroacetic acid (100 
ms mixing time, 800 and 850 MHz 
cryoprobe).  The NMR solution structure 
of IRIS-IP is being elucidated based on 
the NOESY and TOCY data and the 
current progress is shown in Figure 53. 
Figure 51. A homology model of the 
IRIS -IP on rat metallophosphodiesterase 
(Prime and Pymol, Schrodinger LLC).
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These NOE data will be analyzed employing the SPARKY program161 and categorized into four 
classes of distance based on signal intensities with reference to an internal standard: 2.5, 3.0, 4.0, 
and 5.0 Å corresponding to strong, medium, weak, and very weak intensities, respectively.   
This interproton distance information will be processed using CYANA 2.1 for an initial 
solution structure calculation and the crude structure will be refined employing CNS 1.3 with a 
NOE
TOCSY
4.35
2.92
2.75
O
NH2
O
N
H
O H
N
O
HN
OH
O
NH
N
H
HN
H2N
O
HN
O
HN
O
NH
SH
O
HN
O
N O
H
N
OH2N
O
N
H
HO
O
H
N
O
N
H
OH
O
H
N
HN
NHH2N
O
N
H
HO
O
H
N
OHO
O
N
H
O
H
N
O
NH2
O
HN
O
NH
HO
O
HN
O
NH
O
HN
O
NH
O
OH
O
HN
HN
N
O
H
N
O
N
H
O
H
N
OH2N
O
N
H
O
H
N
HO
O
N
H
NH2
O
H
N
HO
O
N
H
HO
HO
Gly-Ile-Gly-Thr-Arg-Phe-Leu-Cys-Leu-Pro-Gln-Ser-Ile-Tyr-Arg-Ser-Glu-Leu-Asn-Val-Tyr-Ala-Phe-Gly-Glu-His -Ile-Leu-Gln-Ile-Ser-Lys-Tyr-Ser
4.29
3.92
7.76
4.14
1.58
1.45
1.21
2.72
8.08
4.35
3.59
7.97
4.22
1.71
1.07
0.81
0.81
4.30 3.93
0.99
7.76
4.28
1.64
1.43
3.04
7.60
3.65
3.58
4.32
8.10
8.25
4.64
2.64
2.47
3.97
7.82
4.64
2.48
2.53 8.24
1.16
4.19
4.49
3.07
2.85 7.79
1.73
0.83
1.08
4.16
7.92
8.01
4.35
2.92
2.75
7.79, 7.75
7.60
7.99
7.79
4.35
8.53
4.28
1.64
1.43
3.04
7.60
Figure 52. The NMR structure of IRIS-IP. Amino acids residues in red indicate ones of which 
assignments are tentatively completed. Numbers denote 1H NMR chemical shift values for 
corresponding protons. Stereodescriptors were omitted for a clearer presentation 
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simulated annealing process.162,163  Among the calculated structures, 20 structures with lowest 
energies without residual restraint violations will be chosen to represent the solution structure of 
the IRIS-IP and their structure quality will be examined by protein structure validation software.164  
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